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Executive summary 
 
Science, technology and innovation are vital to poverty alleviation and improved health. However, although improving 
immediate access to health care and existing health technologies is essential, simply importing technologies and 
products is not enough to create sustainable health care systems. Countries also need to build the capacities and 
institutions to develop their own technology and innovations which are tailored to local needs.  
 
But for innovation to meet local needs, countries need to develop dynamic and integrated health innovation systems. 
This is for several reasons. 
 
Firstly, there tends to be a profound lack of understanding between those in the world of healthcare and those who work 
in health innovation and production of pharmaceuticals. And unless researchers and producers network with local users 
and consumers, they are much less likely to respond to local needs.  
 
Secondly improved innovation capacity that responds to the needs of users does not occur in isolation – it is not the 
product of one-off scientific inventions, heavy investment in science or one-off policies. Rather it is dependent on 
networks through government institutions, private companies and a wide variety of end-user groupings at national, 
international and sectoral levels. Finally, knowledge is not accumulated and built up in one set of institutions and 
transferred to another set – it results instead from the interplay between different organisations and institutions.  
 
There is now an unparalleled opportunity to address both the issues of neglected diseases and to develop such integrated 
health innovation systems. Huge investments are currently being made in global health programmes which seek to 
improve health services and health innovation systems.   The challenge for African policymakers is to adopt strategies 
for integrating global programmes with local and regional health innovation systems. 
 
From our analysis of existing innovation systems, networks and country experiences, we suggest the following 
conclusions and policy recommendations around building health innovation systems in Africa:  
  
 
1. There is a major disconnect between innovation systems and health care systems within the policy arena in 
many African countries. This needs addressing if successful health innovation is to take place. 
 
There is a worrying gap between social policies on the one hand and industrial and innovation policies on the other. 
This gap exists everywhere – even in countries like India and Brazil which have developed strong health innovation 
systems - but it is wider in countries with weaker research bases.  
 
Health policy and national healthcare systems tend to treat innovation as irrelevant because health products can be 
bought anywhere in the world. However this means most drugs, and even the most basic hospital and clinic equipment 
and instrumentation, are imported.  
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On the other hand, S&T policy has not generally focused on health matters because health has not been fully recognized 
as being strategically important to national growth in many countries. Many science and technology policies are still 
only weakly linked to economic and social priorities.  
 
In addition ‘pro-poor’ aid policies – especially for less developed countries – focus mainly on social sector distribution 
and operate almost entirely without reference to policy thinking on promoting innovation and productivity.  
 
Having said this, there is increasing recognition across Africa that science and technology is an important part of the 
health system, and that countries must develop their own research and development capacity if they are to achieve 
sustainable health systems and the Millennium Development Goals.  
 
However for health innovation systems to directly serve the needs of local populations then industrial and innovation 
policies designed to increase productive capacity need aligning with social and health policies designed to address 
distribution. In turn social policy can enhance innovative capacities. 
 
Policy recommendations: 
 
1. The African Union and NEPAD may consider initiating an expert group to develop analysis and promote policy 
initiatives and mechanisms to integrate health related industrial and innovation policy on the one hand and healthcare 
policy on the other hand. The expert group would formulate policy plans and stimulate activities. The group would 
include policy makers, private sector actors and academics. 
 
2. Design some of the Short-term Executive Workshops for Senior Government Officials suggested in the NEPAD 
Science and Technology Consolidated Plan of Action, around building health innovation systems and the need to bridge 
the gap between different areas of policy.  
 
 
2. Building national health systems of innovation must be done within the context of regional and international 
institutions – they cannot be built in isolation. This is particularly important as it is now possible to make use of 
both global and South-South initiatives to help develop new pathways of innovation.  
 
Regional health innovation networks which link different groups working on the same health problem are evolving 
across Africa. Establishing solid collaboration between national institutions and these regional initiatives is vital to the 
sustainability of the innovation networks – and therefore to successful innovation.  
 
Global health programmes provide African countries with significant opportunities to develop new pathways of 
innovation. 
 
Huge investments are currently being made in global health programmes which could help to foster innovation and 
integrate better the health services and health innovation systems. This is because the programmes focus not only on 
producing new technologies for treatment but also on delivering them to huge populations.  
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Global initiatives such as the International AIDS Vaccine Initiative are encouraging capacity building in developing 
countries because they see their success as dependent on the support and involvement of local actors. Linked to this, 
both the Global Fund for HIV/AIDS, Tuberculosis and Malaria and Global Alliance for Vaccines and Immunisation 
recently called for more ‘systems’ building in developing countries, because both recognise their future and the 
sustained success of their operations depends on better health services and systems in developing countries.  
 
The challenge for these global programmes - which would be revolutionary if they succeed - is to develop integrated 
systems that build on existing services and capabilities rather than act as a parallel system which further fragments 
national and regional systems.  
 
As part of this process, global health programmes could help to bind governments and voluntary health sectors with 
local research institutes and universities. But for this to happen, they need to build on each of the six determinants of 
innovation outlined in our paper (see point 6 below).  
 
A challenge for African countries is how to use the new resources to change their health innovation systems 
sustainably. For this to happen, African institutions need to avoid passive sub-contracting and instead actively learn 
from, and take part in, the global initiatives and partnerships in order to innovate, not just imitate, and to construct 
lasting global connections. 
 
Innovation does not occur within strict geographical boundaries. It is affected by international markets and regulatory 
frameworks, as well as cross-national trading and capacity related opportunities and constraints. At the same time the 
development of regional and international health innovation networks is already providing the catalyst for successful 
research, development and access to drugs, vaccines, and health services in Africa.  
 
Policy recommendations:   
 
1. We recommend that NEPAD and the African Union pursue further discussion with international global health 
programmes like the Global Fund and Global Alliance mentioned above about how these initiatives could best support 
health innovation capacity building in African countries. Similar discussions could take place with some of the large 
public private partnerships such as the International AIDS Vaccine Initiative or the Medicines for Malaria Venture.  
 
2. The international community has a vital role in building health innovation systems in Africa. International policy 
needs to recognise the importance of building health innovation systems in Africa and international funds need to be 
targeted to this end.  
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3. National health systems of innovation involve a complex interplay between macro, micro and sectoral level 
actors. A problem-orientated approach is required that addresses issues at all three levels.  
 
National health innovation ecosystems are made up of macro, sectoral and micro level systems. At the macro level 
government institutions and policies and other key institutions influence the rate and direction of innovation.  
International institutions also shape innovation at a macro level, for example, the World Trade Organisation’s Trade 
Related Intellectual Property Rights framework. The sectoral level system consists of the institutions, rules and norms 
of national health systems, and operates within health and health innovation policies. Finally micro level systems are 
created by individuals companies and organisations working in health.  
 
It is crucial that policymakers reconfigure macro environments and sectoral policy to encourage and facilitate vibrant 
initiatives and maximise learning. Also they need to acknowledge the limits of formal planning mechanisms – 
innovation emerges from sometimes competing combinations of technological, institutional and organisation change, 
not according to pre-planned models. Innovation is a fluid activity which is not rule bound or rule led and emerges 
within a flexible macro environment which includes supportive organisational, regulatory and financial models. 
 
It is also important that technology micro initiatives (e.g. work on stem cell research, microbicides, vaccines, 
bioinformatics) are integrated.  
 
Health innovation networks, which link groups from different sectors around a particular health problem, are an 
important part of health innovation systems. Existing health innovation networks are fluid and operate within and across 
national, sectoral and micro levels of systems of innovation. Collaboration is at the heart of these networks. While 
innovation requires a strong knowledge base – good research institutes and universities – that knowledge will not 
automatically be transferred upstream to the creation of products without strong links with other sectors and a dynamic 
interplay of users and producers of knowledge at different stages of the innovation cycle.  
 
It appears from our analysis that the most effective networks are Mode 2 structures of innovation. These are problem-
oriented structures of different stakeholders innovating towards social and economic needs. They link academics, 
applied and product development researchers and user groups, ensuring more is achieved working together towards a 
goal than by going it alone. One example of this Mode 2 structure is the KEMRI-Wellcome Trust Research Programme 
in Kenya. 
 
Many of the existing Mode 2 networks emphasise capacity building and strengthening of a wider health innovation 
system in which they are a part, and also create opportunities for this to occur.  
 
Policy recommendations: 
 
1. This paper has argued for the need to identify and back ‘micro-systems of innovation’ while at the same time 
reforming national institutions and policy to provide facilitative innovation environments. This means rethinking the 
way in which much policy is made – its formulation needs to become a more dynamic and interactive process. One 
policy recommendation is for the African Union and NEPAD to support exercises such as Foresight which might help 
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identify promising initiatives and technologies. Foresight exercises tend to work best when large numbers of 
researchers, scientists and policy makers take part. 
 
2. We also recommend that African universities adopt more Mode 2 approaches to innovation networks and prioritise 
links with other researchers, user groups and policymakers to promote and extend health innovation networks. By doing 
this, African universities could make a fundamental contribution to the development of more sustainable health 
innovation systems.  
 
3. Universities clearly play a key role in providing training in innovation policy and practice that could improve health 
innovation over the medium and longer term. The Consolidated Plan outlines plans for postgraduate training in 
innovation and one policy recommendation that we offer would be to offer a modular strand of training on health 
innovation systems and integration with health systems.  
 
 
4. There is no one innovative framework or pathway that all countries can apply. Each country has individual 
and differing responsibilities, characteristics, opportunities and constraints. 
 
 
5. Having said that, Africa can learn from the experiences of more advanced developing countries. However, 
learning does not just involve imitation but requires 'intelligent engagement'. 
 
This paper looks at the experiences of Brazil, China, Cuba, India and South Africa. Although these include regional 
‘giants’ and therefore we should be wary of simplistic calls for ‘imitation’ and knowledge transfer, African countries 
can learn a lot from the ways they have built their research and development and industrial capacities.  
 
They have all built system-making connections around the six determinants mentioned in point 6. But they found that 
progress in one of these determinants requires progress in most or all of the other determinants.  
 
Despite the success of these countries in developing pharmaceutical and health biotech industries, most have only been 
partially successful in meeting their overall development goals in health. Healthcare for the majority in India and China 
for example has not improved as dramatically as their industries. This is because their industrial and innovation policies 
designed to increase productive capacity have not been aligned with their healthcare policies.  
 
In Africa, this disconnect has different dynamics with access issues being addressed completely separately from 
industrial or innovation policy. 
 
Cuba is a good example of a developing research infrastructure which responds to local needs by promoting strong links 
between the research system and the health delivery system. Major hospitals, for example, are partners in the health 
biotechnology cluster, which means this cluster consists of both users and producers of health biotechnology.  
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6. The six determinants outlined in the paper, together with the missing determinant of organisational capability, 
should be considered in any review of, and attempt to build, a national system of health innovation.  
 
There are six determinants which influence innovation systems: research and development, manufacture, domestic 
markets, international markets, intellectual property and regulation. The lack of functioning institutions in these areas is 
one of the main factors restraining Africa’s technological development.  
 
Several reports, including that of the Millennium Task Force on Science, Technology and Innovation, suggest it is key 
to work on all fronts simultaneously. Developing the six determinants separately without dialogue or connection is 
slower and will not work if the idea is to link the satisfaction of health needs with the capacity to deliver them.  
 
Therefore it is critical to build capacities in all six areas in systemic ways that link healthcare issues with innovation 
policies. Country studies show that it is difficult to progress in research and development capability, for example, 
without first increasing manufacturing capability or without having a domestic or export market to generate resources 
for investment in production facilities.  
 
Policy recommendation: 
 
1. Our final policy recommendation, therefore, is that NEPAD encourage and support the development of policies for 
all seven determinants, gaining agreement that these be developed at national, regional and sectoral levels. 
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1. Introduction 
 
In this introduction we discuss the following questions: 
- What are innovation systems and what is innovation systems thinking?  
- How can we think about building a national system of health innovation?  
 
Science, technology and innovation (STI) are crucial to economic and social development. Simply importing new 
technologies is not a solution for building the expertise and capacity needed to put science and technology to productive 
use and make it work in the interests of developing country populations. The premise of this paper is that improving 
immediate access to health care and health technologies is essential but not sufficient for sustainable health 
improvement and poverty alleviation. The use, adaptation and creation of health technologies and innovation are 
fundamental to Africa’s ability to deliver better health care to its people. One essential challenge for policymakers is to 
harness technologies and innovation to the needs of Africa’s diverse populations. Health innovation systems 
perspectives can help in meeting that challenge. 
 
Innovation systems thinking tells us that success in innovation is not the product of one-off scientific inventions, heavy 
investment in science or particular organisations and policies. Rather, sustained success in promoting and delivering 
productive innovation depends on linkages and networks running through government institutions, private companies 
and a wide variety of end-user groupings at national, regional and sectoral levels. Innovation does not occur in isolation. 
The pattern of particular innovation systems will depend on political, economic and cultural factors. This has major 
implications for national policy makers and points to the importance of creating ‘innovation friendly’ national 
institutional environments. Oyelaran-Oyeyinka articulates the connection between institutional environments and 
innovation saying, 
“Innovation has long been recognized as a social process shaped by institutional structures in which it is 
embedded… The institutions that support technological advance are thus extremely important for long-term economic 
growth, since technology mediates the introduction of new products and processes into the economy. In an industrially 
dynamic context, changes in machinery and equipment will be accompanied by new institutions… in a situation of 
economic backwardness, changes to institutions are rare, just as technological innovation itself may be equally rare, 
even non-existent.” (Oyelaran-Oyeyinka, 2005:8) 
 
The emphasis of innovation systems thinking is on the continuous incremental build up of innovation capacities across 
different actors and institutions rather than on one-off inventions. It points in the direction of a focus on building up 
‘absorptive capacity’1 and learning rather than the acquisition of discrete technologies or highly specialised scientific 
and technical skills. The key point is that economic and social development requires improved institutional capacity in 
innovation so that consumer and user needs are articulated to producers and researchers who can respond. This does not 
mean that each African country needs to undertake all their own health related production and research. It does mean 
that as Africa increases commitments to health provision, countries should focus not only on access to medicine but 
also increase their role in research and development (R&D), production and learning in relation to user needs and link 
into regional and global networks wherever possible. It means that capacity building, training and policy formulation 
                                                 
1 Absorptive capacity refers to the ability to search and make use of new knowledge and new technology. 
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must be rooted in outward looking institutions and must focus on dynamic linkages and interactions that result in 
innovation. 
 
There is currently an unparalleled effort by global health partnerships, the United Nations, public private partnerships 
and bilateral agencies to address the issues of neglected diseases and endemic health problems in Africa. The challenge 
is to grasp the opportunity to build functioning health systems and health innovation systems that will enable African 
populations to benefit from quality health products and services on a more sustainable basis.  
 
1.1 National policy environments, innovation systems and micro-innovation systems 
 
An essential feature of innovation systems thinking is the focus on the interaction between public and private sectors 
and the complex interactions and feedback mechanisms between different elements of the value chain and users. 
Alternative strands of analysis highlight various characteristics and different system ‘boundaries’. One summary of 
definitions of systems perspectives is as follows: 
“The systems of interacting private and public firms (either large or small), universities and government 
agencies, aiming at the production of science and technology within national borders. Interaction among those units 
may be technical, commercial, legal, social and financial, in as much as the goal of the interaction is the development, 
protection, financing or regulation of new science and technology.” (Niosi et al, 1993, p.212)  
 
A large section of the innovation studies literature deals with nationally bounded innovation systems (Nelson, 1993; 
Lundvall, 1992). These studies describe the ways in which national institutions (both structures such as hospitals, 
government ministries, finance institutions and also rules and regulations) influence the ways in which innovation does 
and does not occur. Whilst national perspectives are key and particularly important in terms of policy thinking, there is 
clearly a problem in drawing analytical boundaries around national systems only. The boundaries identifying exact 
systems are clearly imprecise. Metcalfe and Ramlogan write: 
“With increasing evidence in the literature that innovation processes are distributed across national boundaries 
an analytical focus on a national system seems something of a conundrum. The national perspective underlying NIS has 
been predominantly adopted on the basis that many institutions, culture, language, common norms, technology policy, 
and education influencing innovation had a national character... But proponents of the approach admit that these 
systems are open and heterogenous and that there can be other levels (local, sectoral) at which they can be analysed... 
Freeman (1995) for example, points to ‘nether regions’, or smaller ‘sub-national regions’ as opposed to upper regions – 
very large ‘regional’ trading blocks such as NAFTA [North Atlantic Free Trade Agreement], or the emerging East 
Asian ‘region’. Nelson and Rosenberg (1993) further argue that the concept of ‘national systems’ may be too broad as 
the system of institutions supporting technical innovation in any particular field may have very little overlap with those 
institutions supporting innovations in another.” (Metcalfe and Ramlogan, 2005). 
 
Whilst it is vital to understand social and economic institutions in terms of national boundaries, scientific and technical 
knowledge works within a range of other geographical and non-geographical boundaries. Other authors emphasise the 
importance of systems properties, and in particular learning characteristics (Lundvall, 1992; Edquist, 1997) that go 
beyond national boundaries. So, for example, a major concern is how knowledge is transferred from domestic and 
international universities or companies to local organisations and institutions. Again whilst not denying the centrality of 
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national systems, others focus on sectors as the primary lens through which to examine systems (Mugabe, 2005; 
Malerba, 2004). The focus here can be on how different sectors, pharmaceutical or engineering say, evolve and what 
sorts of institutions, organisations and linkages characterise different sectors. Yet another approach looks at how 
innovation takes place within clusters and industries or technologies (Oyelaran-Oyeyinka and Rasiah, 2005; Kiggundu, 
2004; Carlsson, 1995).  
 
Cutting across these different notions of non-geographically bounded systems Metcalfe and colleagues (2004) talk 
about ‘micro-innovation systems’. This concept indicates that innovation systems at the national level co-evolve with 
many ‘micro-innovation systems’ or innovation based initiatives, projects and enterprises. An example of the relevance 
of the concept to this paper are the global health partnerships which can be thought of as micro innovation systems 
connecting across national and regional boundaries and assisting in some cases with the building of capabilities in 
relatively weak national environments. This paper adopts conceptual tools from a variety of systems perspectives to 
look at the development of health innovation systems within national and regional contexts.   
 
At the heart of innovation systems analysis is a concern with knowledge accumulation and how knowledge and research 
pertain to economic and social development which has enormous implications for policy. What sort of education may a 
country want to deliver to its citizens for instance. Theoretical physics may be felt to be essential for a healthy 
intellectual environment and yet Nobel Prize winners in theoretical physics will of course be of limited use in 
improving hospitals. A theoretical physicist for instance will probably not understand how to engineer a laser machine 
for use in hospitals even though she may understand the principles upon which such a machine should operate. 
Research biochemists can build understanding of how certain chemicals may change biological states, but they cannot 
alone design new drugs.  In any innovation process a mix of skills and perspectives are required. Yet, in Africa, 
experiments in mixing more vocational or problem-based learning with more theoretical and academic perspectives are 
few and far between. Mytelka and Oyelaran Oyeyinka (2003) identify higher education institutions as one of the 
barriers to innovation in the African context saying that the inherited colonial pure scientific model of tertiary education 
in Africa is seemingly unable to be adapted to serve current innovation needs. Many, although importantly not all, 
national and regional initiatives have proved unsuccessful in creating flexible institutions that can respond to pressing 
social and economic problems. 
 
These more conceptual issues translate to immediate and pressing realities. Health systems and health innovation 
policymakers need to grapple with issues of whether new initiatives should be regional or national or local. Should they 
be grounded in traditional understandings of ‘academic excellence’ or should they be rooted in practical activities and 
applications of knowledge? These issues are the heart of the challenge involved in creating ‘systems’ and networks that 
will facilitate innovation in health and other sectors. Identifying a conceptual apparatus to help construct useful 
institutions is key. If we cannot be precise about geography (national, regional or local) and about which ‘systems’ or 
‘models’ that we can deploy, how do we use systems concepts to help in the process of creating useful institutions and 
networks in health innovation? 
 
One way forward, which we have already began to explicate, distinguishes between ‘innovation ecologies’ representing 
the sets of individuals, organisations and knowledge repositories in any national context and the “‘system making’ 
connections that ensure the flow of information...” (Metcalfe and Ramlogan, 2005)    
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For the purposes of this paper we will translate and use the concepts outlined above (see Table 1) as follows: a macro 
environment or ‘ecosystem’ made up of national institutions (including norms and behaviour patterns) and 
organisations, rules and patterns of behaviour to describe say, major Kenyan public or private institutions; sectoral 
systems made up of health institutions and organisations to illustrate say, the Ugandan health system and; multiple 
‘micro-systems’ that forge purposeful links and interactions to explain say, the International AIDS Vaccine Initiative 
(IAVI) or KEMRI (the Kenyan Medical Research Institute), for example. If we push the ecosystem analogy further we 
could say that the pattern of ‘selection’ by micro-systems (the extent and manner in which national institutions and 
organisations are used by micro-systems) will, in the manner of natural selection, determine which national and sectoral 
level institutions will thrive. There is then a need for policies that can sensitively build connections. 
 
Table 1 – The (National) Health Innovation Ecosystem 
 
 Macro level system Sectoral level system Micro level system  
Defined 
as: 
National innovation 
system 
Sectoral/ cluster/ technological 
innovation system 
Micro Innovation System 
 
World Trade 
Organisation (WTO) 
Trade Related 
Intellectual Property 
Rights (TRIPs) 
framework 
Institutions, rules and norms of 
National Health Systems 
Individual firms and 
organisations working in 
health research, care, 
financing and delivery 
  
A
ct
or
s/
A
ct
an
ts
 
National government 
policy on innovation  
Health and health innovation 
policies 
Initiatives around the 
production of e.g. ARVs 
System
 m
aking connections 
 
1.2. Health innovation systems 
 
‘Health innovation system’ is an overarching term that includes relevant aspects of the macro environment of 
institutions, pertinent rules and procedures within a national system of innovation, the activities of health institutions 
within a national health system and the micro level innovation activities of individual companies and organisations 
involved in the health care value chain including production, delivery, financing and research.   
 
The report of the Millennium Project Task Force on STI highlights the importance of technology and innovation to 
health: 
“A broad number of health interventions require the development of new treatments and vaccines through 
improved science (e.g. anti-malarials, HIV treatments and prevention, drug-resistant tuberculosis, vitamin and other 
micro-nutrient deficiencies in children and mothers, etc). In addition, the production of generic medicines holds the 
promise of improving the poor’s access to essential medicines. A particularly important contribution of science and 
technology in this area lies in improved monitoring systems for pharmaceutical quality.” (2005, p.36) 
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The report also considers that the challenge of improved technology and innovation lies in the capacity of policymakers 
to tackle issues systemically, building innovation systems that facilitate, promote and respond to developments. A 
special Nature Biotechnology supplement in 2004 made a powerful case for building up health innovation systems in 
developing countries as part of the effort to develop innovation appropriate to the needs of the world’s poor 
(Thorsteinsdottir, 2004). Development of innovation and manufacturing capacity in Brazil, India, Cuba, South Africa, 
South Korea and China for instance has lead to significantly increased research and product development for diseases 
afflicting countries in Latin America, Asia and Africa. 
 
In thinking about health innovation systems an analytical and policy focus is required that is informed by the more 
general ‘systems’ framework set out in the previous section. The ways that national innovation systems impact on 
health care and innovation needs consideration. A wide range of institutions that impact on health will have varying 
relevance in different national contexts: educational and policy infrastructure, intellectual property frameworks, 
financial facilities, social welfare and insurance provision, broad economic policy etc. We need to consider sectoral 
institutions such as hospitals, drug distribution networks etc. Without the basic health systems, the effectiveness of any 
other interventions including global health partnerships will be limited.2 The whole value chain associated with health 
provision is thus extremely complex, including science labs, many highly industrialised, to health services, over the 
counter and private providers of all kinds, including top hospitals where much incremental innovation takes place. 
 
Figure 1 outlines the different elements of a health innovation system that influence the rate and direction of change and 
which are influenced by the numerous ‘micro systems’ in development at any one time. Figure 1, and the analysis in 
this paper, point strongly to the need to think about the linkages between users and producers of health care. For 
example, policy changes relating to financial restructuring or intellectual property (IP) rights management might have 
profound impacts on people’s access to medicines and also on domestic capacities. One important aspect of systemic 
perspectives is the attention paid to mismatches and gaps and the potentially contradictory effects of policies:  
“In resource constrained developing countries, the consequences of government policies to improve access to 
medicines and to promote access to needed medicines through promotion of generic versions of branded products, may 
be in conflict with policies to promote a domestic pharmaceutical industry as part of a larger industrial policy. There are 
important practical and policy distinctions among: a) promoting access to medicines (which we define as the process of 
(re)distributing to needy patients those medicines available somewhere in the world); b) creating the necessary research 
and development to discover or develop innovative medicines in the first place; and c) developing an industrial base to 
make medicines locally. These three goals may, or may not, be aligned with each other. Indeed, the responsibility to 
stimulate R&D and promote local industry is most often discussed in terms of industrial, rather than health, policy.”  
(Kaplan and Laing, 2005) 
 
This quote highlights the fact that in policy terms there is a worrying and endemic gap between social policies on the 
one hand and industrial and innovation policies on the other hand. Dealing with such disconnects3 is vital. Development 
and the ending of mass poverty and disease require a massive increase in productive capabilities and production in 
developing countries. Some countries, notably in Asia, are achieving this. Yet ‘pro-poor’ aid policies, especially for the 
least developed countries, focus strongly on social sector distributional mechanisms and operate almost entirely without 
                                                 
2 A meeting at Wilton Park in the UK hosted high level discussion on this issue at the end of 2006.  
3 For example where industrial and innovation capacity is being created but not addressing local health and social needs. 
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reference to policy thinking on promoting innovation and productivity. Conversely, researchers on innovation and 
industrial policies tend to know little about the potential for social protection to support innovation and productivity 
improvement. Thus there tends to be a profound lack of understanding between those who research and make policy in 
the world of health care and provision of health services and goods and those whose interest is in health innovation and 
production of pharmaceuticals. Several authors have begun to tackle this divide (Mackintosh, Chataway and Wuyts, 
2007; Mkandawire, 2007; Gore, 2007). 
 
Figure 1 – Influences on the health innovation system 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Mytelka, 2007 
 
If health innovation systems that directly serve the needs of local populations are to be created this gulf needs bridging. 
Industrial and innovation policies designed to increase productive capacity need aligning with social and health policy 
designed to address distribution. Social policy can in turn enhance innovative capacities (Mkandawire, 2007). In recent 
publications both Thandika Mkandawire from UNRISD and Charles Gore from UNCTAD urge policymakers to adopt 
policy frameworks which view social policy and distributive mechanisms as development opportunities.   
 
Mackintosh and Tibandebage (2007) in a paper drawn from a careful study of health care markets and providers in 
Tanzania conclude that informalisation and market liberalisation had created incentives for perverse provider 
behaviour; associated with heavy reliance on private providers this was inhibiting innovation and efficient and effective 
provision of health care. The market incentives encouraged rather than discouraged poor quality provision and illegal 
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activities. The authors point out that while there are now high level demands for investment in health systems and 
innovation systems, policy in the Tanzanian and other contexts undermine system capabilities.  “Active support for 
health system integration and organisational sustainability and probity is essential for poverty-focused care and 
innovation, and will require major investment and deliberate structural change after many years of deregulation and fee-
based finance.  Policy should aim to constrain perverse market dynamics and move towards system integration” 
(Mackintosh and Tibandebage, 2007:23) 
 
Thus, thinking about health innovation systems requires some revision of the traditional demarcations between 
production and provision in creative ways. This view is endorsed by both NEPAD’s health and science and technology  
(S&T) strategies. As John Mugabe puts it: 
“The notion of a health innovation systems, is… more than just the sum of the R&D institutions, health care 
organisations and medical scientists and practitioners, but includes also the policy regime that determines how well 
there are mutual interactions among various actors. It is a system with changing actors, connections and interactions” 
(Mugabe, 2005:11) 
 
We will now briefly explore some of the main features of health innovation systems in Africa.  
 
 
2.  Health Innovation Systems in Africa  
 
In this section we discuss: 
- The six determinants of an innovation system 
- The importance of building an integrated system 
- The role of organisational capacity 
 
The NEPAD health strategy paints a daunting picture of the situation in Africa.   
“The HIV/AIDS epidemic poses an unprecedented challenge for Africa, reversing the gains made in life 
expectancy over the past half a century. Life expectancy in the most severely affected countries has been reduced by 
almost a third, from 60 years to 43 years. 2.4 million people died from AIDS in 2002 and around 3.5 million infections 
occurred… 1 million deaths [are] caused by malaria each year and 600,000 deaths caused by tuberculosis. Malaria has 
slowed economic growth by 1.3% per annum at a $12 billion economic cost. Countries have a tuberculosis burden 
exceeding the 300 per 100,000 population benchmark for severe disease, with 1.6 million new active cases occurring 
annually. Sleeping sickness is resurging, affecting between 300,000 and 500,000 people annually.” (NEPAD Health 
Strategy, 2003) 
 
The challenges, to different degrees, impact on all African countries. The continent is of course extremely diverse and 
health systems and innovation capacities differ greatly but health systems in many contexts are impoverished and 
fragmented. Capacities to undertake scientific and technological development relevant to local diseases and local needs 
is very low in many contexts.   
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2.1 Six dimensions of health innovation systems 
 
Six major areas influence innovation systems in different countries: R&D; manufacture; domestic markets; international 
markets; IP and regulation. It is critical to building capacities in each of these areas in systemic ways that tries to link 
healthcare delivery issues and concerns with innovation policies and issues so that both might meet local needs calls for 
new approaches and initiatives. This section provides a very schematic overview of the existing state of affairs in each 
of these six areas and then points towards some of the new approaches that are being developed and how systemic 
approaches can be built when attention is given to these six determinants. 
 
2.1.1 R&D  
Determining scientific capacity and levels of research and development is not straight-forward. A 2001 Rand report 
provided an assessment of scientific capacity and indicators of levels of R&D in developing countries based not only on 
the usual patent and citation data. Rather the report attempted a more sophisticated and accurate measurement based on 
a comprehensive index of capabilities. These included: The per capita gross national product (GNP) as proxy for 
general infrastructure; the number of scientists and engineers per million people to capture the human resources 
available for S&T activities; the number of S&T journal articles and patents produced by citizens of that nation to 
characterise scientific outputs; the percentage of GNP spent on R&D to measure the society’s level of input into S&T; 
the number of universities and research institutions in the nation per million people to characterise the infrastructure for 
S&T; a measure of the number of the nation’s students studying in the United States adjusted for those who chose not to 
return home at the conclusion of their studies to characterise the country’s contact with external knowledge sources; and 
the number of patents filed through the U.S. Patent and Trademark Office and the European Patent Office (Wagner et al 
2001). 
 
Countries were categorised into four groups. There are no African countries listed in the 22 countries that made up the 
‘Scientifically advanced countries’ group. Only four countries in Africa are grouped as having built, or as being in the 
process of building, their scientific capability; South Africa was placed in the ‘Scientifically proficient group’ while 
Egypt, Benin and Mauritius where seen as ‘Scientifically developing countries’. (Wagner et al, 2001). 
 
John Mugabe notes that only a few developing countries possess the necessary capability to engage in scientific 
research and in the development of medicines or manufacture of pharmaceuticals: “in Africa it is South Africa, Egypt 
and Kenya that possess capability to conduct drugs research” (Mugabe, 2005:7). Nevertheless as Mugabe points out and 
as other sections in this paper will show, there are R&D initiatives taking root in Africa and there is a base to build 
upon.  
 
2.1.2 Manufacturing 
Industrial competitiveness is much of Africa is poor. Manufacturing value added per capita is not only lower than most 
developing country regions of the world, but contrary to global trends, it is not growing. Table 2 shows this. 
 
John Mugabe notes that in Africa, only South Africa and Egypt have local companies engaged in some pharmaceutical 
manufacturing activities. Algeria had reported capability to produce pharmaceutical products such as oral liquids, 
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tablets, capsules and ointments. This potential has not yet translated into capacity because of the absence of a strong 
industrial production base. (Mugabe, 2005:7) 
 
In an overall assessment of constraints on health innovation capabilities in Africa, Mugabe notes the following as 
important factors: lack of any policy focus on health R&D; low levels of investment in R&D in health with most 
developing countries spending less that 0.5% of their GDP on health R&D and weak links between public health R&D 
institutions and private industry. (Mugabe, 2005:9) 
 
Table 2 – Manufacturing values 
 Manufacturing value added per capita  
(in US$ adjusted to 1995 values) 
 1990 2002 
Industrialised economies 5,161 5,839 
Transition economies 863 596 
Developing economies 221 356 
East and South-East Asia 247 576 
South Asia 48 75 
Latin America and the Caribbean 670 674 
Middle East and North Africa 273 365 
Sub-Saharan Africa 99 89 
Excluding South Africa 33 33 
 (Source: Pietrobelli, 2006) 
 
2.1.3 Domestic markets 
Markets in Africa are dominated by both public and private institutions, involving both state dominated provision of 
goods and services and increasingly also involving the private sector operating on the basis of commercial rules. The 
large scale of private funding and provision of healthcare in Africa also involves an important role for non-
governmental providers (Bloom, 2004; Bennet et al 2005). Markets also include as actors, Non-governmental 
Organisations (NGOs), donors and multilaterals.   
 
On a global scale the Africa market is very small. In pharmaceuticals the global market is worth over $406 billion, 77% 
of which is in the US, Europe and Japan. Only 1% of total spending occurs in Africa, which accounts for 25% of the 
disease burden in the world (Scheffler and Pathania, 2005). There is little large-scale regional production of 
pharmaceuticals in Africa due to a lack of capacity and expertise to produce not only the drugs needed but also vaccines 
and diagnostics. These figures lead to the coining of the phrase 10/90 gap to illustrate how only 10% of all health 
research and development is spent on issues affecting 90% of the world’s population. What spending there is in Africa 
on health related R&D is increasingly funded by public sector institutions and through new organisational forms called 
‘public-private partnerships’ (Moran, 2005). This is because the private sector pharmaceutical companies find it too 
costly and risky to invest in development of drugs for diseases affecting those in the developing world, so-called 
‘neglected diseases’, where demand is high but ability to purchase drugs is low (Trouiller et al, 2002).  
 
 19
A wide diversity of policies exist to encourage positive private sector engagement in African health. Policies include: 
promotion of private corporate investment in African health systems, as in the 2006 International Finance Corporation 
initiative; support and regulation initiatives to change small providers’ behaviour, such as the Tanzanian Food and 
Drugs Authority initiative to train staff, accredit and locally monitor a network of rural drug shops; and numerous small 
scale insurance initiatives. Mackintosh and Tibandebage (2007) however note that although all of these schemes depend 
on good market information, the “field research-based and analytical literature on the operation of the private health 
sector in developing countries remains thin”. They go on to talk about two negative features of the way liberalised 
markets operate drawing also on a broader cross-country study of health care commercialisation (Mackintosh and 
Koivusalo, 2005):  
“First, health care is dominated in all sectors by formal and informal fee-for service provision… in general, the 
poorer a country, the larger the expected share of health funding represented by out-of-pocket spending... In Tanzania 
an estimated 45% of all health care spending is private expenditure, largely out of pocket. Second, liberalisation of 
clinical provision has been associated with the expansion of informalised private provision on which large numbers of 
poor people depend. By ‘informalisation’, we mean a lack of enforcement of basic regulatory constraint including 
registration requirements; very poor clinical oversight and supervision; absence of quality assurance in provision and 
medicine sales; and at worst, a shift of health care into an informal sector of unlicensed, unstable and abusive services 
and drug sales… 
…This combination of charging system and provider behaviour has resulted in a crisis of access and quality of 
health care that was severe even before the recent wave of out-migration of health professionals from low income 
countries…” (ibid.) 
 
What Mackintosh and Tibandebage highlight is the need to think through the implications of sets of policy that cover 
access to medicines with those that promote production of medicines. Clearly, you need innovation in delivery systems 
at low income levels, as well as technological innovation. If access policies are serving people poorly, it is impossible 
to get new technological developments and innovations to those people. Where scientific and technological innovations 
could contribute enormously to testing and quality supervision ‘informalisation’ of systems may hinder efforts to put 
technology to use. There is a need to consider factors influencing both supply and demand within healthcare.  
 
2.1.4 International markets 
International markets in generic drugs are of vital importance to Africa. For example with the bulk of HIV/AIDS 
infection affecting those in African countries, the production of cheap anti-retroviral (ARVs) drugs is vital. The 
production of generic or non-patented drugs for controlling HIV/AIDS by Indian companies has reduced the cost of 
these antiretroviral drugs by 97% (Henry and Lexchin, 2002) making them more affordable for HIV positive 
populations in African countries. The cheapest regimen, a fixed dose combination of stavudine, lamivudine, and 
nevirapine, decreased in price from US$350 annually in 2001 to $168 in 2004, and was selling at between $132 and 
$148 in 2005/6. The price of combinations of zidovudine-lamivudine and efavirenz decreased more slowly and is 
currently around $400. Second-line drugs remain even more expensive, with an average price of $900 in least 
developed countries and $1600 in middle-income countries in 2005 (Schwartländer et al, 2006).  
 
The production of generic ARVs made in Africa is small – limited to Kenya and South Africa with Tanzania starting in 
2006. The wider branded drug market is also small. A number of countries (particularly, South Africa, Kenya and 
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Nigeria) have local production capacity and some international pharmaceutical companies have licensing agreements 
with African companies to produce their products in Africa.  However, local drug markets are dominated by imported 
drugs from India.  
 
However although African pharmaceutical companies are expanding and partnering with larger international firms, 
there are still numerous access issues. The factors impacting international and Northern based pharmaceutical 
companies’ activity in producing essential medicines for African countries also affects companies in Africa e.g. price, 
quality assurance and IP rights. As such pharmaceutical companies in Africa may follow in the footsteps of their 
Northern hemisphere and Indian colleagues and increase production of drugs where they can make a profit and which 
respond to the changing epidemiological transition away from ‘diseases of poverty’ to more lucrative products targeting 
heart disease and obesity or as South Africa is doing and move into ‘health tourism’. Particularly of note is the fact that 
IP agreements inhibit sales. As the ongoing disputes over IP and HIV/AIDS drugs show, there is a struggle over 
Africa’s access to IP protected drugs definitions of what constitutes national emergencies and when compulsory 
licensing might be called for and so on. 
 
2.1.5 Regulatory capacity in Africa 
Regulation is fundamental to the provision of good quality pharmaceuticals and healthcare. Failure to regulate and 
monitor presents obstacles both in contexts where new treatments and drugs are being developed and in ensuring 
consumers’ rights. Building capacity in regulatory and monitoring mechanisms is fundamentally important as African 
countries attempt to supply appropriate treatments to its people. Most countries in Africa have a drug regulatory 
authority as Table 3 shows. 
 
The World Health Organisation (WHO) is concerned that while all countries in Africa have national drug regulatory 
agencies, the majority of them have limited capacity (SAIIA, 2005). For example, Dr Jean-Marie Prapsida of the WHO 
Regional Office for Africa noted that even the South African Medicines Control Council, touted as the reference point 
for other African agencies, still has limited capacity, especially for monitoring and evaluating clinical trials. Limited 
capacity has resulted in countries being unable to enforce proper drug regulations, putting at risk the health of millions 
from improper drug use, all this happening in the backdrop of mounting complexities from killer diseases such as 
malaria, tuberculosis and HIV/AIDS. Additionally, some multinational corporations conducting clinical trials in Africa 
have bemoaned the weak drug regulatory capacity in Africa, with Boehringer Ingelheim, for example, failing to register 
its single-dose nevirapine in the USA after some clinical trials in Uganda. Some irregularities with data recording and 
improper reporting were highlighted, and the company had to withdraw its registration application (SAIIA, 2005).  
 
The WHO notes that part of the solution to these challenges lies in strengthening medical control councils and 
regulatory bodies to enable them to offer adequate support and to monitor trials effectively. In 2003, the WHO started a 
programme to assess the weaknesses of drug regulatory agencies in Africa in order to come up with the best measures 
for assisting them. The WHO also offers on-going capacity building through universities, especially aimed at human 
resource-capacity building, but they have no direct authority, as according to Tim Farley of the WHO, they ‘do not want 
to undermine the work that goes on at national level’. The WHO also provides the latest available information to 
countries to assist them in their decision-making processes. In their programme on Strengthening Drug Regulatory 
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Authorities (DRAs)4, the WHO provides the following: assessment of National Regulatory Systems; Practical manuals; 
Training Courses, Model websites for DRAs; Model system for computer-aided drug registration; Certification scheme 
for the quality of drugs moving on the international market and; the biennial WHO international conference for drug 
regulatory authorities. For example, Kenya (www.pharmacyboardkenya.org), Tanzania (www.tfda.or.tz), Uganda 
(www.health.go.ug/national_drug) and Ethiopia (www.daca.gov.et) have benefited immensely from the activity on 
developing model websites for drug regulatory agencies. The available capacity in each country also determines to what 
extent they can tap into and benefit from these initiatives. 
 
Table 3 – African Drug Regulatory Authorities 
Country Type of DRA  Country Type of DRA 
Benin Direction Des Pharmacies   Angola National Medicines Directorate 
Botswana Drug Advisory Board / Drug Regulatory 
Unit 
 Congo Direction des Service Sanitaires 
Burkina Faso Directorate of Pharmacy and Medicine  Eritrea Medicines Control & Regulatory Services 
Cameroon Pharmacy & Medicines Department, 
Pharmacy & Drug Directorate 
 Equatorial Guinea Aprovisionamiento de Medicamentos 
Cote D’ivoire Directorate of Pharmacy and Medicine  Liberia Pharmacy Board of Liberia 
Djibouti Ministry of Health  Lesotho Medicines Control Authority 
Ethiopia Drug Administration & Control Authority  Madagascar Agence du Medicament 
Gambia Medicines Board  Malawi Pharmacy, Medicines & Poisons Board 
Ghana Food and Drugs Board;  Pharmacy 
Council of Ghana 
 Mauritius Pharmacy & Drug Regulation Dept, 
Ministry of Health 
Libya Drug Regulatory Authority  Morocco National Laboratory for Drug Control 
Mali Direction Pharmacie et Medicament  Namibia Drug Control Unit, Ministry of Health  
Mozambique Pharmaceutical Dept, Ministry of Health  Niger Direction Generale de la Pharmacie 
Nigeria National Agency for Food & Drug 
Administration and Control 
 Senegal Direction de la Pharmacie et des 
Laboratories 
Papua New 
Guinea 
Medical Supplies Branch, Ministry of 
Health 
 Togo Direction Generale de la Sante Publique 
Sierra Leone Pharmacy Board of Sierra Leone  Kenya Pharmacy Board Kenya 
Somalia Ministry of Health  Egypt Drug Policy & Planning Centre 
South Africa Medicines Control Council  Guinea Diretcion Nationale de la Pharmacie et du 
la Laboratoire  
Sudan General Directorate of Pharmacy  Rwanda Pharmacy Services, Ministry of Health 
Tanzania Pharmacy Board 
Tanzania Food & Drug Administration 
 Swaziland Pharmacy Services, Ministry of Health 
Tunisia Directorate of Pharmacy & Medicine  Central African 
Republic 
Inspecteur des Services Pharmaceutiques 
Uganda National Drug Authority  Zimbabwe Medicines Control Authority 
Source: Table generated from data in proceedings of the WHO International Conference for Drug Regulatory Authorities (1996, 
1999, 2002 and 2004) 
 
                                                 
4 http://www.who.int/medicines/areas/quality_safety/regulation_legislation/en/ 
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Thus, the WHO provides extensive advice on how regulatory authorities should be constructed, making it clear that it is 
national Ministries of Health who are charged with formulating and implementing regulatory provision.   
 
However, the requirements for drug regulation as set by the WHO are not being met by many African countries. The 
problem relates to inadequate human, financial and infrastructural resources. This scenario makes it difficult for the 
drug regulatory authorities to cope with demand especially in light of increasing pressures of technological 
developments which mean that new products are being placed on the market at an increasing rate. The challenge to 
ensure quality, safety and efficacy is not one that most African regulatory authorities are meeting effectively. Recent 
studies have highlighted the importance of regulation in health innovation and have differentiated between regulatory 
approaches that constrain on the one hand and enable innovation on the other (Tait et al, 2005; Chataway et al, 2006).   
 
2.2 From separate determinants to building integrated African ‘health innovation systems’ 
 
Systems of innovation frameworks revolve around the importance of collaborative networking between actors/actants at 
different levels of innovative activity and learning capabilities. Linked to this are the ‘system making’ connection 
components or the purposeful activity around the six determinants outlined above that create linkages between the 
actors within the health innovation system. We now examine a case example of Niprisan (NICOSANTM) to highlight 
the interplay of these six determinants with the different actors within a health innovation system. It also demonstrates 
that productive ‘system-making’ initiatives are possible even in difficult circumstances and that the challenge is to 
maximise the potential of these successes. 
 
2.2.1 Niprisan for Sickle Cell Anemia 
Sickle Cell Disease (SCD) is an inherited blood disorder caused by an abnormality in the hemoglobin molecule. The 
disease changes the shape of red blood cells carrying oxygen through the body resulting in pain and anemia. Those with 
the disease suffer a higher than average frequency of illness and premature death, especially in infancy.  
 
Nigeria probably has the highest sickle cell disease population in the world (four to six million, roughly three to five 
percent of the population). More than 100,000 Nigerian children are born each year with the ailment. As a result, since 
the early 1990s, SCD topped the list of priority research projects of Nigeria’s National Institute for Pharmaceutical 
Research and Development (NIPRD). In 1993, NIPRD established collaboration (contractual agreement) with a 
traditional health practitioner and commissioned a clinical study (1993-2001) using plant abstracts. From the findings of 
the study, ‘Niprisan’ was developed by NIPRD. 
 
Niprisan is a drug cocktail, with phyto-pharmaceutical composition of four traditional plants extracted in a proprietary 
process. It has been patented in 46 countries and is jointly owned by NIPRD and the traditional health practitioner. The 
funds for patenting and conducting R&D of the drug were provided by the UNDP. In July 2002, Niprisan was licensed 
to XECHEM Inc., an Indian pharmaceutical company based in the USA, by the Nigerian Federal Ministry of Health. 
Xechem Nig. Ltd (a subsidiary of Xechem Inc.) commenced local production of Niprisan in 2003. Further 
pharmacological studies have resulted in standardization of Niprisan into capsule dosage form. In this new form, the 
drug has been approved, under the name NICOSAN™/Hemoxin, by Nigerian drug regulators, the National Agency for 
Food and Drug Administration and Control and launched in Nigeria for sale on July 6th, 2006. Nicosan/Hemoxin has 
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received orphan drug status from the US Food and Drug Administration (in 2003) and by its European equivalent (in 
2005). 
 
The journey of Niprisan, from plant extract to medicine in capsule dosage form, and from a traditional health 
practitioner in Nigeria to global markets demonstrates success in developing a range of systems-building capabilities. 
Nigerian insitutions have effectively used the intellectual property system to leverage financial and social benefits from 
the country’s natural resources. National R&D expertise customized to address a specific domestic problem has also 
lead to some global success. Technology transfer links have been made with national public research institutions in the 
process of the production of Niprisan in Nigeria by Xexhem creating a potential income stream in the form of royalties 
and other revenue flowing from the agreement with Xechem as well as building local R&D infrastructure. 
  
Systems-making connections have been made between NIPRD, traditional health practitioners, local community 
members (during trial activities), UNDP which provided a sizeable grant, hospitals and clinicians, patent agents who 
facilitated the patenting of the product in multiple markets, and a private firm. 
 
While it offers potential as a case to learn from and build on, it has been argued (Oyelaran-Oyeyinka and Gehl Sampath, 
2007) that many public research institutions like NIPRD still suffer from poor funding and subsequent lack of facilities 
for biotechnology-based research as well as weak institutional mechanisms. For example, until recently, the Nigerian 
government showed little interest in funding R&D providing only 10% of NIPRD’s research funds. Many public 
research institutions suffer from weak institutional and regulatory infrastructure to conduct meaningful partnerships 
with, for example, holders of traditional medicinal knowledge or to test for efficacy and safety of traditional 
preparations. Similarly, at times, there is still weak private sector interest in drug development and few spin-off 
companies created from public research institutions.  
 
2.3 The missing determinant: organizational capacity? 
 
The Niprisan case study highlights a need to look beyond the market. It illustrates the need to focus on building and 
maintaining organizational and learning capacity within and between the different actors. International partnerships 
afford opportunities but maximum impact requires national and regional institution building and improvement. Several 
large international networks, in which African countries participate, place emphasis on building capacity within health 
innovation systems, albeit in different ways. These networks e.g. IAVI, Medicines for Malaria Venture (MMV), Drugs 
for Neglected Diseases initiative (DNDi) and the South African AIDS Vaccine Initiative (SAAVI) are involved in the 
production and clinical testing of new drugs and vaccines for diseases affecting African countries. The R&D capacity in 
many African countries is, at present, insufficient to perform such studies. Thus one pressing challenge for both 
government and private sectors is to construct funding and institutional mechanisms that effectively facilitate enhancing 
capacity. Activities that focus on creating local capacities would involve building physical capacity, training staff, 
developing lab-infrastructure, improving microbiological and immuno-diagnostics, promoting good clinical practice 
and ethics infrastructure, and will involve north-south as well as south-south capacity building activities.  
 
For example SAAVI is a national level public private partnership (PPP) set up in 2000 to develop an effective and 
affordable HIV vaccine for the surrounding region and is made up of the South African government, public sector 
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research organisations, private sector companies and financiers. SAAVI has worked on more than just developing a 
vaccine. With an emphasis on collaboration and strengthening knowledge capacities, SAAVI has built scientific 
research capacities in skills, knowledge and products in the laboratories, academia and in clinical trials. It has also built 
stronger health systems mainly through its trial sites operations by creating advanced infrastructure, facilities and 
trained staff. The combination of capacity building and collaboration between different sectors has produced important 
knowledge flows and absorptive capacities between disparate and discrete sectors. These knowledge flows occur within 
and across S&T, policy, community and health actors.  
 
Another interesting project from a systemic capacity building viewpoint is The Tanzanian Essential Health 
Interventions Project (TEHIP). The project essentially aims to link S&T and other forms of capacity building into 
broader health systems through the creation of computer based data collection and analysis of burden of disease 
statistics to aid policy making at the district level. TEHIP demonstrates the importance of integrating research and 
capacity building and of working in an interdisciplinary fashion that brings together varied skills (social, scientific, 
economic) together with management knowledge.  
 
A recent initiative that promotes south-south linkages for capacity building is the African Poverty Related Infection 
Oriented Research Initiative (APRIORI). APRIORI aims at establishing a state-of-the art clinical research centre in 
Tanzania by involving African Centres of Excellence in Mali and Ethiopia with assistance from a number of Northern 
based institutions. Strengthening south-south collaboration the programme aims to build capacities and establishments 
for malaria, tuberculosis and HIV/AIDS. Streamlining of activities on these three diseases to obtain internal cohesion, 
collaboration and cross-fertilisation, the programme aims to utilize existing knowledge and innovative research (new 
tools and strategies). The strong links between centres of excellence from Africa (through south-south initiatives) and 
Europe (through north-south initiatives) which merges into research and capacity building besides facilitating 
knowledge flows is very innovative. 
 
The Global Health Research Initiative - HIV/AIDS Prevention Trials Capacity Building grant recently instituted also 
aims to build capacity in African institutions to conduct HIV/AIDS prevention trials by supporting the development of 
both new and existing partnerships between African and Canadian research teams. The focus of the grants is to build 
and enhance individual and institutional competencies required to conduct high quality research, and to build site 
capacity to conduct planned and anticipated trials in Africa, in particular related to research on, and development of, 
prophylactic vaccines, microbicides and other preventive interventions. The programme has the specific objective to 
promote and support partnerships between interdisciplinary teams of Canadian and African researchers. Grants under 
this initiative are intended to be complementary to other global investments (e.g. Gates Foundation, National Institutes 
of Health and European Union initiatives) and therefore will not fund prevention trials themselves, but rather capacity 
building related to conducting such trials. 
 
As these cases illustrate there is no one model for building capacities but rather a diversity of approaches that can be 
pursued. These approaches point to the importance of local stakeholder involvement. Although international (public 
private partnership) efforts are important they cannot substitute for local efforts and in this context local capacity 
building is a serious concern. The key issues that need to be addressed to develop successful and meaningful capacity-
building programs include: understanding the local context and facilitating local operations; strategising a mix of short-, 
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medium-, and long-term interventions; and thinking and encouraging the development of systems of innovation. Local 
strengths must be built on, and efforts must be tightly related to, local problems and infrastructure. But building on 
existing capabilities in local contexts involves a range of time scales and time-bound planning (short-medium-long 
term) that progresses and builds the local innovation capacities (skills, capabilities, and institutional infrastructure) in a 
systematic way.  
 
It is evident from the literature that Africa has made progress in S&T. Many countries have shown positive action by 
creating dedicated ministries for S&T, and these ministries have produced policies for implementation. However, in 
many cases such policies are not integrated with other sectoral policies, and therefore, involve separate strategies that 
have no link to national (health) development. Also many of these actions are still designed or greatly influenced by 
international financial institutions and donor countries and they are not always appropriate in the local context. Lack of 
functioning institutions is one of the main factors restraining Africa's technological development.  
 
 
3.  Learning from others 
 
In this section we discuss the following question: 
- What can be learnt from policy in developing countries that have developed health 
innovation capacities? 
 
A number of developing countries, notably Brazil, China, Cuba, India and South Africa, have advanced in health 
innovation, following different paths to create selective capacities and capabilities in the pharmaceutical and health 
sectors. They have created a number of ‘system making’ connections linking the institutions and individuals working 
within the macro, sectoral and micro levels of innovative activity. The initiatives taken by these countries show some 
homogeneity such as building of education and health systems, investing and creating large reservoirs of specialised 
scientific skills within health sectors, long term planning of R&D activities; and creating research networks within the 
country. They are not meant to be uncritically followed. Indeed, their relatively high resource levels for developing 
countries make that impossible. Our case studies and analysis of some of the system making connections and capacities 
below provides better understanding of the successes and failures of these countries and from which valuable insights 
can be learnt. 
 
3.1 Brazil 
 
Brazil has invested in health related biotechnology since the early 1970s and has emphasized the importance of health 
research since 1900 with the establishment of a federal institute, the Oswaldo Cruz Foundation (known as Fiocruz,). In 
the 1970s the government’s National Research Council launched two biotech programmes which were followed in the 
1980s by the National Biotechnology Programme that integrated all those working on biotechnology in a programme 
dedicated to capacity building. The result is a strong public sector dominated biotechnology and health research base, 
predominantly based out of the main universities of San Paulo, Rio de Janeiro and the Federal University of Minas 
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Gerais. The dominant independent public research institutes are Fiocruz and the Institute Butantan based in San Paulo. 
(Ferrer et al, 2002)  
 
Private sector investment in health research and particularly biotechnology has risen rapidly since the 1990s. During the 
1990s the number of biotechnology firms in Brazil increased more than four-fold from 76 firms in 1993 to over 350 in 
2001 (ibid.). However, although Brazil has a large pharmaceutical market as well as a growing private biotechnology 
sector, interaction between these and the public sector has only recently been encouraged with the passing of an 
Innovation Law (see Box 1). This reversed a previous law that made illegal public sector researcher employment by 
industry firms.   
 
One strength of Brazil’s strong public sector health research based around universities and other academic institutes is 
strong human resource capacity. Fiocruz creates not only a large number of highly trained personnel with skills to 
produce world-class innovation but also accumulates scientific knowledge and absorptive capacity that strengthens and 
builds the Brazilian innovation system. However, the lack until recently of opportunities for knowledge exchange 
between the public and private sectors limited the degree to which knowledge exchange took place. Although the 
introduction in 1994 of National Conferences on STI in Health created national dialogue on the issue, bringing together 
not only the Ministries of Health, Education and Science and Technology but also involving representatives from 
research institutes and the general public. These Conferences have been used to set the agenda for research around 
health related STI in Brazil and the base for which government funds and calls for research proposals are based.   
 
The STI Conferences and the new Innovation Law exemplify the importance of links between different actors within 
the Brazilian health innovation system, providing a good example of the creation of links between the welfare system 
and the innovation system (da Motta, Albuquerque and Cassiolato, 2001). Brazil appears to have recognised that the 
health innovation system is not simply made up of those organizations, institutions, rule and norms influencing the 
purely scientific innovative process of R&D and product development. It emphasizes the importance of a systemic 
approach that works to build systems making connections at every, and between, all levels of the innovative process.   
 
Brazil’s commitment to health innovation and provision of health services to its population has enabled it to play a 
policy role internationally. Along with India, South Africa and others, Brazil has argued strongly on behalf of 
developing countries in the context of WTO discussions. Brazil is a leading member of south-south networks dedicated 
to producing and distributing better products and treatments for neglected diseases. These include the South to South 
Box 1 - The Brazilian Innovation Law 
 
Following consultation the Brazilian Innovation Law was introduced in October 2005. The law reverses a situation 
that made illegal public sector research staff employment by private sector firms thus incentivising partnerships 
between public and private research institutes. The law also aims to encourage participation of public sector research 
institutes within the innovation process more generally, as well as innovation between private companies particularly 
through intellectual property rights and licensing agreements.  For example, the Innovation Law created the 
opportunity for product development, as with Acheflan, an anti-inflamatory cream developed by a private sector 
Brazilian drug company, Ache, through collaboration with a university research base. Acheflan was Ache’s first 
patent-protected bio-medical innovative product. Ache has gone on to develop other partnerships with Brazilian 
universities. 
(sources: Ryan, 2006; www.scidev.net; www.wipo.net)
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HIV/AIDS Technological Cooperation Network and the (India, Brazil, South Africa) IBSA dialogue forum which 
considers issues of trade and intellectual property. 
 
3.2 Cuba 
 
Particularly since the 1985 publication of ‘Good Health at Low Cost’ by The Rockefeller Foundation, Cuba’s health 
system has been championed for its cost-effective performance. Part of its success is due to the building up and 
integration of its health research sector into the healthcare system, particularly in the area of biotechnology. In the last 
two and a half decades, Cuba developed significant national capacity in biotechnological knowledge and infrastructure. 
In focusing on developing national research capacity with Cuban scientists and professionals, the first priority of 
biotech research is the domestic market, meaning that the Cuban people themselves directly benefit from the country's 
medico-scientific expertise. This concern with the well being of the local population goes hand in hand with developing 
new medical products for export. For example, in the early 1980s, Cuban R&D programmes led to the first and only 
vaccine for a particular strain of meningitis which was used to stem a local outbreak in the mid 1980s.  Further research 
into meningitis vaccines resulted in Cuba becoming in the 1990s the first country to develop and market a vaccine for 
meningitis B. It is currently delivered to 30 countries, including China, India, Russia, Pakistan and many Latin 
American countries (Thorsteinsdottir et al, 2004). More recently, Cuba produced the world's first human vaccine with a 
synthetic antigen that protects against Haemophilus influenzae type B infection, which often leads to pneumonia and 
meningitis in children under the age of five. 
 
New biotechnologies were expected to facilitate product diversification and import substitution at a time when the 
collapse of the Soviet Union and the U.S. trade embargo forced it to develop home-grown solutions to local health 
problems. The development of a national capacity of biotechnology was also seen as a strategy to increase sovereignty 
and independence from transnational companies of the industrialized countries. This is not to say that Cuba has not 
collaborated with international companies. One of Cuba’s premier research centres, the Carlos Finlay Institute 
collaborates with GlaxoSmithKline (GSK) to develop and distribute the meningitis B vaccine. Future examples of such 
efforts could encompass the development and dissemination of vaccines for AIDS, cholera, dengue and other diseases. 
Researchers at Cuba’s Center for Genetic Engineering and Biotechnology (CIGB) and the Finlay Institute are making 
substantial progress in these and other areas. New partnerships with Latin American and other countries including 
China and industrialized countries mean that Cuba is at the forefront of developing drugs for international users and 
markets. 
 
The Finlay Institute (see Box 2) is an example of how Cuba's development model is based on harnessing the nation's 
wealth in human resources and science to create a knowledge-based economy focused around health. Since the 1959 
revolution, the cornerstone of the country's social development has been education and health care. Beginning in the 
early 1960s, biotechnology and medical research became a top priority of the Cuban government, with over one billion 
dollars invested in biotech R&D in the 1990s alone. Today, Cuba boasts a ratio of 1.8 scientists per 1000 inhabitants, a 
level comparable to the European Union (though with a far smaller Gross Domestic Product) (Hurlich, 2003). There are 
38 biotech centers, grouped together in a science park to the west of Havana, which integrate research, development, 
production and marketing. Cuban students and specialists are educated and trained in the most technologically advanced 
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countries like USA, France, Japan, Switzerland, Canada, Mexico, England, Germany, and Finland contributing to the 
impressive knowledge base that exists today in Cuba. 
 
 
 
3.3 China  
 
Extensive government reforms in the late 1970s and early 1980s - including policies that began to shift the nation from 
a centralized, planned economy towards a market-based one - identified the science system as central for the country’s 
modernisation and economic development (Zhenzhen et al, 2004). China has created giant industrial districts in 
distinctive entrepreneurial enclaves. Niche cities (Beijing, Shanghai, GuanZhong) reflect China's ability to form 'lump' 
economies, where clusters or networks of businesses feed off each other, building technologies and enjoying the 
benefits of concentrated support centres. The Chinese government has played a central role in promoting capacity 
building and innovation in the health and biotechnology sector. In 2002 China established its pharmaceutical S&T 
policy covering the period 2002 to 2010.   
 
Like Cuba, an emphasis has been placed on building up the capacity of China’s health biotechnology innovation 
system. The origins of modern biotechnology research in the country can be traced to the late 1950s policy of the ‘great 
leap forward’. Health biotechnology industrialization was not widespread until after the mid 1980s, but expanded 
rapidly when some public research institutes were transformed into enterprises for manufacturing medicines. Under the 
ninth Five Year-Plan in 1997 the health biotechnology research system received increased financing and support to 
build up institutions and research capacities as an effort to establish a National System of Innovation (MIHR, 2005). At 
present there are about 500 Chinese public and private sector biotechnology firms. Emphasis is placed on building up 
human resource development not only through higher education facilities but also through the public research institutes. 
A central role is given to the Chinese Academy of Science which conducts research, education and training activities. 
China’s strong public education and research programmes are driving innovation in both state owned enterprises and 
the burgeoning number of private enterprises. 
 
Parallel to this has been the growth of the Chinese pharmaceutical market. This is one of the world’s largest markets, 
second only to Japan in Asia and is expected to become the world’s fifth largest by 2010. The growth of the 
pharmaceutical output has been phenomenal in China in the last decade with an annual average growth rate of about 
Box 2: The Finlay Institute 
 
The Finlay Institute has become an essential component to Cuba's vaccine research and production efforts. Its most 
successful and best-known product is the vaccine against meningitis B and its current meningitis B and C 
combination vaccine. As part of the Cuban National Immunization Program, 10 of 27 vaccines currently in the 
research phase in Cuba are being developed at the Finlay Institute. Previous successes in coordination with institutes 
such as CIGB have included development of vaccines against tetanus toxoid, leptospira, and hepatitis B. In 2002, the 
Finlay Institute developed a new vaccine against typhoid fever, similar to one produced by Belgian and French 
pharmaceutical companies. The Finlay Institute is currently working with GSK on clinical trials of its meningitis B 
vaccine in both Europe and Latin America, with hopes of extending trials to the United States. Along with the 
financial benefits received by the Finlay Institute, there is also the political and symbolic importance of a developing 
country vaccine being used in the north. The VA-Mengoc-BC vaccine is a good example of the need to step beyond 
narrow international constraints to work for a higher purpose and the benefit of humanity. Finlay Institute researchers 
are currently involved in applied microbiology, molecular biology, fermentation processes, vaccine development, 
and immunology. 
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20% over the past 15 years. The domestic pharmaceutical industry has been a key contributor to the country's 
staggering economic growth. There are approximately 6,800 Chinese pharmaceutical firms, of which, 5,000 produce 
medicines and the remainder are involved in packaging and equipment supply. However, due to an emphasis placed on 
public sector investment in biomedical science and research, the Chinese private pharmaceutical sector has remained 
high fragmented and has suffered from substantial shortages of investment capital to undertake high risk product R&D. 
Public Sector focus has been strongly on research rather than development. Recently, the Ministry of Commerce 
announced plans to build 100 export-oriented “innovation bases” for the pharmaceutical sector by 2010. By offering 
financial and technical support and facilitating the entry of Chinese firms into international markets, the strategy aims to 
bolster Chinese exports of high-tech products while fostering domestic innovation in the pharmaceuticals. 
 
 
 
Special attention has been given to traditional knowledge and mechanisms to use this resource as a base for the 
biotechnology and pharmaceutical sectors. The protection and domestic commercial exploitation of traditional 
knowledge is an important issue in China. Traditional medicines are used by large portions of the population and have a 
significant role in public health. One such medicine is Artemisinin - the frontline treatment for malaria (see Box 3). 
Used for centuries as a traditional medicine to treat malaria a Chinese pharmaceutical firm is collaborating with 
Novartis to produce modern malaria drugs. However, weak patent policies and regulations as regards to these have led 
to a loss of materials to foreign research. Increasingly China is acknowledging the importance of robust and inclusive IP 
policies in this area to ensure protection of its indigenous knowledge and often return of rewards to its communities 
sometimes in the form of trust funds that have nurtured this area. 
 
3.4 India 
 
The Indian pharmaceutical industry produces a wide range of complex pharmaceutical formulations and over 400 active 
pharmaceutical ingredients. The industry ranked fourth globally in terms of volume and thirteenth in terms of value at 
an estimated US$ 6.0 billion in 2004 (IMS Health, 2004). But until the 1970s, India had virtually no domestic 
Box 3 - Artemisinin 
 
The herb Artemisia annua has been used for many centuries in Chinese traditional medicine as a treatment for 
fever and malaria. In 1971, Chinese chemists isolated from the leafy portions of the plant the substance responsible 
for its reputed medicinal action. This compound, called qinghaosu (QHS, artemisinin), has been used successfully 
in several thousand malaria patients in China, including those with both chloroquine-sensitive and chloroquine-
resistant strains of Plasmodium falciparum malaria. Derivatives of QHS, such as dihydroqinghaosu, artemether, 
and the water-soluble sodium artesunate, appear to be more potent than QHS itself. Sodium artesunate acts rapidly 
in restoring to consciousness comatose patients with cerebral malaria. Thus QHS and its derivatives offer a totally 
new class of antimalarials.  
 
In 1991, Novartis (then Ciba-Geigy) began collaborating with Kunming Pharmaceuticals on Coartem (derivative) 
production and obtained marketing approval in 1998. Novartis partnered with WHO in 2001 to make Coartem 
available in malaria-endemic countries on a not-for-profit basis. According to WHO, since the Global Fund for 
HIV/AIDS Tuberculosis and Malaria (GFATM) began disbursing funds in 2003, the demand for combination 
therapies based on artemisinin has increased rapidly and led to a drug shortage in late 2004. Since 2001, Novartis 
has supplied more than 10 million treatments. “The original 2001 agreement forecast demand for Coartem at just 
over 2 million treatments in 2005… Since then, nonbinding demand forecasts provided by WHO have 
continuously increased, including a sixfold jump between December 2003 and March 2004, when the 2005 
forecast surged from 10 million to 60 million treatments.” (Hans Rietveld, global marketing manager for tropical 
medicine with Novartis) 
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pharmaceutical industry producing drugs from basic raw materials, relying heavily on imports. The ‘access to 
medicines for all’ perspective that ruled Indian thinking in the 1950s and 1960s (Amsden and Cho, 2003) and the need 
to build self-sufficiency in local antibiotic production provided the starting point for change. 
 
Liberalization in the 1990s further facilitated a shift from an import-substitution economy to an export-oriented one, 
enabling the emergence of a competitive domestic industry and set the foundation for world-class generic drug 
production capabilities in India. Private firms gradually advanced to creative imitation stage (chiral synthesis) during 
the early 1990s and started to enter and establish themselves in regulated markets (mainly USA and Europe). Signing of 
the TRIPs agreement and transition to product patent regimes since 1995 has facilitated research in the Indian 
pharmaceutical firms to enhance their R&D focus and spend on new drug delivery systems and new chemical entities. 
 
Currently there are 5,877 pharmaceutical private companies operating in India. The organized sector consisting of 250-
300 companies accounts for 70 percent of products in the market with the top ten companies (out of which 9 are Indian) 
representing 30 percent. Approximately 75 percent of India’s demand for medicines is met by local manufacturing 
(KPMG, 2006). Over the years, the co-evolution of policy and innovation in the public and private sector have 
contributed to India’s rapid development of pharmaceutical and biotechnology (Chaturvedi and Chataway, 2006) with 
the development of industry-institute linkages and private investments for biotechnology ventures. Indian institutes and 
public research labs not only provide the scientists and technicians for the sector's workforce, but also contribute 
research discoveries of relevance to pharmaceutical and biotechnology firms. Traditionally, the role of universities was 
in education and training, whereas laboratories, both public and private, focused on research. Today, the lines are 
blurring, as universities incorporate research activities and national laboratories provide training for students to join 
industry later on. A good example of such blurring is seen in the Indian Institute of Science (IISc), Bangalore. Its 
department of biochemistry is working on immunology, reproductive biology and plant development as part of the 
study of diseases such as malaria, rabies and tuberculosis, as well as carrying out applied research on drug targets and 
vaccines. The 1990s saw a flourishing of numerous institutes and laboratories dedicated to biotechnology. Some of the 
most active in health biotechnology include the National Institute of Immunology and the Institute of Microbial 
Technology and the IISc. All these Institutes have multiple joint projects and collaborations with domestic as well as 
international drug giants. Market pull and government push for innovation in health research has enhanced PPPs 
tremendously in the recent past and the cumulative impact of these factors on knowledge creation and knowledge 
diffusion is unquestionable. 
 
Scientific achievements in the field of biotechnology have been very encouraging and of direct relevance for the 
specific challenges of India’s needs. For instance, the Hepaptis B vaccine was first developed by a small biotech firm, 
Shantha Biotechnics, in 1993 (see Box 4) with government aid and since than more than 300 biopharmaceutical 
products have been put on the world market (STI, 2006). According to a recent survey there are 96 exclusive 
biotechnology enterprises operating in India, making the Indian sector the third largest in Asia. The sector is a diverse 
mix of private domestic small and medium sized enterprises, such as Shantha Biotech and Bharat Biotech; larger firms 
like Biocon and Dr. Reddy’s, Ranbaxy and Wockhardt; and some public enterprises including Haffkine Bio-
pharmaceutical and Indian Immunologicals (Kumar et al, 2004). The result of public and private efforts has been the 
creation of a large pool of highly qualified personnel and world class biotech and pharmaceutical infrastructure.  
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3.5 South Africa 
 
South Africa has explicitly incorporated systems thinking into its innovation strategy. The strategy was implemented 
following the adoption of a White Paper on Science and Technology in 1996 and the setting up of the Department of 
Science and Technology (DST) (see Box 5). The White Paper placed science and technology innovation within the 
broader macroeconomic context within which South Africa was operating, emphasizing competitiveness; job creation 
and human resources; quality of life; environmental sustainability; the information society and knowledge embedded 
products and services. Thus an integrative approach was taken. As mentioned in the section on Brazil, South Africa has 
been a leading member of policy oriented efforts to create global policy mechanisms to support national innovation 
efforts in developing countries. 
 
The DST has encouraged working with stakeholders to develop health research priorities through a National Research 
and Technology Foresight Project and National Science and Technology Forum as well as collaborative research 
programmes such as the South African Malaria Initiative and SAAVI (discussed in Section 2) together with numerous 
efforts to encourage dialogue with and between academic, industry and policymakers.  
 
Significant and creative efforts have been made to link science funding into innovation and to support more systemic 
approaches and initiatives. Recently the DST has supported the creation of a Biotechnology and Health Working Group 
which is a non-governmental ‘trouble-shooting’ group dedicated to taking “a leadership role to advance efforts designed 
to make South Africa a more significant participant in the global biotechnology and biomedicines industry, to address 
the country’s public health requirements and to stimulate innovation in biotechnology”.5 
 
Two DST activities of particular note have been the efforts to promote competitiveness through the introduction of an 
Innovation Fund and the emphasis placed on incubators and regional innovation centres within the 2001 National 
Biotechnology Strategy. The Innovation Fund was designed to encourage innovation at the later stages of the product 
development pipeline. As such to act as a venture capitalist investing in projects which due to the high risk of later stage 
                                                 
5 Meeting at Africa Genome Education Institute, October 2006 
BOX 4: Shantha Biotech  
 
Shantha Biotechnics, an Indian biotechnology start-up, began research for an affordable indigenous vaccine in 
1993. A western company had earlier denied the technology assuming that India did not have the resources to pay 
the high technology fee for buying the vaccine nor the ability to absorb the technology. Initially initiated as an 
R&D exercise at Osmania University, under the industry-university interaction programme the research was 
subsequently conducted at the Centre for Cellular and Molecular Biology. Since biotechnology was a relatively 
unknown segment and there were no venture capitalists around at that time, funding proved difficult. The project 
finally received funding from the Sultanate of Oman of 50 per cent equity. It also received a long-term loan from 
Oman International Bank. Later, a loan was organized for technology development and commercialisation. 
Shantha Biotechnics launched India's first recombinant hepatitis-B vaccine, Shanvac-B, in 1997 followed by 
Shankinase (recombinant Streptokinase). Apart from supplying the product all over India, Shantha Biotechnics 
supplies it to various other countries directly and also through UNICEF agencies after Shanvac-B received the 
WHO-Geneva pre-qualification. The indigenous development of recombinant hepatitis-B vaccine enabled India to 
join the select club of five countries in the world to have the know-how to produce hepatitis-B vaccine. Shanvac-B 
was a huge national success since it developed a vaccine for local health needs, bringing down the prices of 
imported vaccine from Rs780 to Rs50 in 1997 and to Rs25 in 2003.  
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development costs may not otherwise have been taken forward. There have been questions raised at the idea of using 
public funds for venture capitalist type activities. A mechanism to encourage innovation in biotechnology has been the 
development of regional innovation centres and biotech incubator hubs. These centres have not yet received the tenants 
that they require to be sustainable. Problems in encouraging start-ups are thought to be partly related to a shortage of 
venture capital funds. 
 
 
Although South Africa is clearly committed to investing in science and technology, expenditure on R&D is still less 
than 1%. Private sector investment in health related biotechnology is low. South Africa’s regulatory system has also 
been widely criticized for slow response times and inefficiency. Siyabulela Ntutela outlines a number of challenges: 
“….the cost of patenting, the sale of intellectual property rights outside of South Africa, the quality of licensing 
agreements and the professional management of intellectual property protection in universities” (Ntutela, 2006).  
 
3.6 Building African health innovation capacities 
 
Clearly these countries are at different stages of development, have public and private sectors of varying degrees of 
maturity and hence are diverse in their approaches. They are also some of the most advanced developing countries, and 
we should be wary of simplistic calls for ‘imitation’ and knowledge transfer. But, African countries can surely learn a 
great deal from the ways in which China, Brazil and India have built industrial and R&D capacity. Cuba provides 
fascinating insight into policy approaches aimed at developing S&T and health innovation for domestic health 
improvement. South Africa is experimenting with systems innovation based policy and more integrated policy 
development. However, it is important to highlight that most of these countries have been only partially successful in 
meeting their overall development goals in health and health innovation.  
 
Each country has undertaken activities that have built system-making connections along the determinants identified in 
Section 2 in attempts to strengthen its health innovation system. What emerges from an analysis of the strengthening of 
their health innovation systems is that the six determinants of the framework are linked in a dynamic manner. Progress 
in one requires progress in most, if not all other determinants. It is difficult to progress in R&D capability without first 
increasing manufacturing capability or without having a domestic or export market to generate resources for investment 
BOX 5: South Africa’s Department of Science and Technology (DST) 
 
Scientific discoveries and the associated development of new technologies are key long-term drivers of economic 
growth and development. Innovation, technology mastery and the diffusion of knowledge and new products and 
services into markets are key elements in this growth and result in sustainable improvements in the quality of life of 
all South Africans. The White Paper on Science and Technology (1996) created the policy framework for the then 
Department of Arts, Culture, Science and Technology (DACST) to establish key enabling policies and strategies to 
inform the strategic development of S&T in South Africa. 
 
In 2002 Cabinet approved the National Research and Development Strategy. The National R&D Strategy requires 
performance and responses in three key areas: 1) enhanced innovation; 2) providing science, engineering and 
technology human resources and transformation; and, 3) creating an effective government S&T system. 
 
It is in this context that the DST has been established as a separate department to ensure that there is greater 
coordination, integration as well as better understanding and management of all government funded science and 
technology institutions and to provide a holistic overview of public expenditure on science and technology. 
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in production facilities (Mahoney, 2005). One of the ways in which developing countries can access new technologies 
for strengthening health innovation is to enter into joint ventures with technology savvy firms in developed countries as 
India and China are aggressively pursuing. South-south collaborations could be an important vehicle to facilitate 
knowledge flows within developing countries as we discussed in section 2. But, as Lall (2003) points out, sophisticated 
foreign firms will gauge their level of willingness to form joint ventures based on the value of the domestic market in 
the developing country, the capability of local R&D centres, and the expected level to which IP will be protected.  
 
While the pharmaceutical and health biotech industries in India and China have shown spectacular growth health 
provision for the majority in those countries has not improved so dramatically. Thus, in some cases industrial and 
innovation policies designed to increase productive capacity have not been aligned with social development despite 
promising policy visions such as “Health For All” and “access and affordability of medicines”. There are serious gaps 
in putting knowledge and policy into practice. The case study of Cuba is perhaps the best example of an attempt where 
policy coherence has, on one hand, supported research infrastructure and strong health and education system and on the 
other hand, has promoted strong linkages between the research system and its health delivery system. The major 
hospitals are partners in the health biotechnology cluster and the cluster has therefore both users and producers of health 
biotechnology. Thus the delivery system is by default an integral part of the health innovation system, and distribution 
and health care services are well integrated into health innovation.  
 
The challenge of improved technology and innovation, as we discussed in section 1, lies in the capacity of policymakers 
to tackle issues systemically, building health innovation systems that facilitate, promote and respond to the local health 
care primarily and possibly global market needs through research and development, manufacturing, distribution and 
services. Reconfiguration of macro frameworks and integration of multiple technology micro initiatives like genomics, 
stem cell research or new products like microbicides and vaccines or even new knowledge fields like bioinformatics in 
health innovation is crucial. 
 
The country cases outlined here have provided strong indicators for the policy, process and practice with examples of 
how system-making connections can build the determinants of an innovation system. It is useful to build local R&D and 
manufacturing capabilities – not just in terms of infrastructure provision through the national innovation system but also 
institutional level organizational capacity to innovate. This needs to take place within the context of the wider 
international arena in which both the national and international (healthcare) markets and economy play out. Regulation 
and intellectual property need to be strongly developed and made relevant to local knowledge and situations.   
 
However the case studies also demonstrate the disconnect between thinking about innovation and industrial policy on 
the one hand and social development policy on the other. In India, China and Brazil policies in these two areas are often 
disarticulated. Huge increases in scientific and manufacturing capacity have not been pursued with reference to changes 
in social development policies so that R&D could serve the immediate needs of populations. In Africa, of course, this 
disconnect is also present but has different dynamics with access issues being dealt with completely separately from 
industrial or innovation policy. It is obvious and relevant also, to note the fact that African countries suffer from huge 
difficulties of weak resources of all kinds and extremely fragile relevant institutions, which will require massive focus 
on core problems, with internal clarity and external support. We return to these issues in Section 6. Before that we will 
consider some initiatives currently trying to match R&D to African needs.  
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4. Health Innovation Networks  
 
In this section we discuss: 
- The globalisation of knowledge 
- Examples of current health innovation networks  
- The capacities required to build sustainable health innovation networks 
 
Innovation does not occur within strict geographical boundaries. It is impacted on by international markets and 
regulatory frameworks, as well as cross-national trading and capacity related opportunities and constraints. Successful 
innovation requires collaborative activity not only at a national level but between countries and increasingly at a 
regional African level and at a sub-regional (e.g. West African) level as well. The form that such collaborative activity 
takes is also important. As such regional and sub-regional, together with international initiatives, are taking shape and 
gaining in strength forming ‘health innovation networks’ providing the catalyst for successful research, development 
and access to drugs, vaccines, diagnostics and health services in Africa.   
 
4.1 The globalisation of knowledge 
 
In acknowledging the fluidity of interactions related to innovative activity it can be argued (Carlsson, 2006) that there 
has been an ‘internationalisation of systems’. Innovation often takes place within a ‘national system of innovation’ 
being influenced by a network of national structures. However regulations and frameworks, and knowledge spillovers 
are increasingly ‘international’. Knowledge is now retransferred across organizations and absorbed from and exported 
to international corporations and other foreign entities (ibid.). This is not only due to the advances in communications 
but also changes in the way healthcare and innovation are taking place. Health issues are seen as increasingly complex, 
ignoring territorial boundaries and requiring solutions that take account of spatial, temporal and cognitive changes (Lee 
et al, 2002) while firms are often multi-national or trans-national. At a smaller scale, advances in communication and 
the rise of internet technologies, have enabled less sizable companies and business individuals to access information 
and markets throughout the world. The relationship between local and global is changing leading not only to 
‘globalisation’ (bringing the global to the local) but also the local influencing the global. The result is multiple, varying 
forms of knowledge and information flow.  
 
4.2 Learning from current health innovation networks 
 
Health innovation networks take no specific form but are the result of interactions with external groups by individual 
entities or industry clusters operating at various levels within national systems of innovation. As such they operate 
within and across national, sectoral and micro levels of systems of innovation. International partnerships, bilateral 
south-south initiatives or regional clusters can all constitute networks. Health innovation networks can also have 
different objectives focusing either on strengthening one determinant of an innovation system specific to their own 
activity (e.g. capacity for R&D) or multiple determinants of a health innovation system as illustrated by the work of a 
number of international health partnerships such as MMV. By looking at how a number of health innovation networks 
operate – how they transfer knowledge, build their organizational structures and network between members – it is 
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possible to highlight how building initiatives across national, sub-regional and regional institutions can facilitate and 
support innovation through establishing solid relationships that are vital for sustainability.  
 
4.2.1 Mode 2 forms of networking 
At the heart of these networks is collaborative activity. Innovation requires a strong knowledge base e.g. good research 
institutes and universities but this on its own is insufficient as there is no pre-determined linear movement of this 
knowledge upstream to the creation of products (Velho, 2004). As we have pointed out at the beginning of the paper, 
innovation is the result of the dynamic interplay of users and producers of knowledge at different stages of the 
innovation cycle. As such traditional ‘mode 1’ or linear based structures of innovation are evolving into more complex 
loose, ‘mode 2’, structures containing numerous stakeholders each with their own skills base in which innovation takes 
place within the wider social, economic and political context (Nowotny et al, 2001). An emphasis in ‘mode 2’ is placed 
on practice based learning oriented towards specific and practical outcomes. An example of a ‘mode 2’ health 
innovation network is the KEMRI-Wellcome Trust Research Programme in Kenya (www.kemri-wellcome.org) which 
is seen as being: 
“…fully integrated into the Kenyan research infrastructure, through its close relationship with KEMRI, in Kilifi, 
the Programme is embedded within Kilifi District Hospital, building its research programmes around local medical 
infrastructure and contributing to healthcare delivery. Researchers are also committed to engaging with the local 
community, to discuss their research and why it is being carried out”. 
 
As outlined in Box 6 further this Programme has numerous stakeholders involved and actively participating at various 
stages of the research process placing its innovation activities within the wider context of the local community 
healthcare needs as well as wider national and international health issues. Here the Programme is just one node within a 
much larger network of institutions working towards the creation of an atlas of malaria and its impacts in Africa.  
 
The non-institutionally based collaboration with numerous other stakeholders throughout Africa on the MARA/AMRA 
Project, and beyond, has not only created useful ‘risk’ maps of malarial illness to inform malaria control policy in the 
region but also built the capacity of researchers within KEMRI-Wellcome and others in the region in geographical 
information systems (GIS) technology and statistical mapping methods. Such activities see knowledge transferred 
across geographical boundaries strengthening the loose organisational structure of the MARA/AMRA Project around 
the production and application of its innovation activities. Here capacity building is not confined – nor is it within 
KEMRI-Wellcome’s other work – to being a linear process of those with the knowledge training those without the 
knowledge. The focus is on the creation of stronger links between researchers and users to ensure that the maps created 
are used effectively and adequately within malaria control policy.   
 
The KEMRI-Wellcome Trust is a nationally based initiative rooted in functioning and linked institutions. This solid 
base however enables it to operate regionally. Thus, even where institutions and organisations are initially set up on a 
national basis they can offer regional benefits and offer an alternative to new institutions which have weak or non-
existent links to a wide range of other R&D and user organisations.  
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4.2.2 Networked health innovation partnerships 
MMV is a health product development partnership that actively networks to strengthen health innovation activities (see 
Box 7). The partnership actively attempts to develop R&D capacity (resolving difficult IP issues and building 
manufacturing capacity) to create useful malaria medicines particularly for developing countries. MMV places an 
emphasis on building up the regulatory environment for clinical trials of potential drug and vaccine candidates and 
works on access issues to ensure the market will be there once drugs and vaccines are developed. Like the IAVI 
partnership (Chataway and Smith 2006; Chataway et al 2007), MMV as an entity works as a broker of innovation 
across existing systems. It works beyond national boundaries bringing together disparate groups who share a common 
interest in advancing malaria medicine innovation but who before now had few avenues for interaction. Its focused 
activities could well result in more general R&D capacity building which will enable those involved to contribute to 
developments in other disease areas. Thus while capacity building is not the explicit objective of MMV, its activities do 
seem to result to some extent in capacity development for local partners.  
 
 
 
In contrast, the European and Developing Countries Clinical Trials Partnership Programme (EDCTP) was set up to 
consider the specific issue of building R&D capacity within developing countries through linkages with European 
BOX 6 – KEMRI and MARA 
 
KEMRI-Wellcome Trust Research Programme 
The link between the UK’s Wellcome Trust and Kenya’s medical research community dates back to 1949 when the 
Wellcome Trust established a research laboratory in Nairobi’s Kenyatta Hospital. KEMRI was established in 1979 
as the country’s main medical research institute. From the late 1980s formal joint work began between the two 
groups focusing on malaria research. The joint KEMRI-Wellcome Trust Research Programme has three main 
principles underlying its activities: internationally competitive research, strong clinical research focus and local 
applicability. Linked to this is a strong emphasis placed on capacity building. The Programme is built around 
partnerships with numerous actors including other international research institutes e.g. at Universities of Oxford 
and Liverpool, the hospitals of Kilifi District and Kenyatta National, the Kenyan Ministry of Health and the local 
communities in which its research centres are based.  
 
The MARA/AMRA Project 
The KEMRI-Wellcome Trust Research Programme is a member of a pan-African research project to map malaria 
risk and endemicity. The MARA/AMRA Project started in 1996. The KEMRI-Wellcome Trust Research 
Programme became a formal node within the Project in 1997 looking at malarial disease burden with a specific 
data centre. In the 10 years the project has been running numerous other data centres have been set up within 
Africa providing a rich source of malaria data contributing to the development of ‘risk’ maps used in malaria 
control policy activities and the geographical modelling of malaria. It has allowed the first accurate assessment of 
the burden of malaria to occur for Africa. The project has set up a number of national centres, undertaken capacity 
building of researchers in GIS technology, climate change methods, databases and conducted end-user training 
workshops. 
BOX 7: Medicines for Malaria Venture (MMV) 
 
Set up in 1999 as a not-for-profit Foundation MMV works to “discovery, develop and deliver new antimalarial 
drugs” by bringing together the public, private and philanthropic sectors in partnerships to conduct research, produce 
and register drugs for the treatment of malaria in disease-endemic countries. It has activities that span the drug 
product development pipeline from basic research to delivery through public-private partnerships with groups from 
around the world. MMV has an in-house team, supplemented by contract research organizations, that manages its 
drug portfolio of over 20 projects. MMV has held 5 rounds of calls for proposals to identify new projects to add to its 
portfolio. It has projects that focus on different species of malaria and requirements for different patient groups and 
therapeutic pathways. Since 2003 MMV has closely collaborated with GSK, a major pharmaceutical company. 
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researchers working on HIV/AIDS, tuberculosis and malarial drugs, vaccines and diagnostics. Although it has an 
explicit capacity building remit the EDCTP has experienced problems, unlike international partnerships such as MMV 
resulting in difficulties dispersing funds (see Box 8).  
 
 
 
4.2.3 Southern-led African based health innovation networks 
A number of health innovation networks extend beyond geographical boundaries linking groups at a sub-regional, 
regional level and at times even international level through the function of ‘globalisation’ so networks originating from 
within a like-minded group of individuals, within or between countries, can create links to form a sub-regional, regional 
or international group that takes its national or regional origins as a base. An example of such a group would be 
AMANET, the African Malaria Network Trust and the AAVP, the African AIDS Vaccine Programme (see Box 9). 
These groups work in different ways and have different goals but they were both conceived as ‘African’ initiatives with 
the goal of building African capacity and opportunity for health innovation.  
 
A similar focus pervades South-South initiatives such as Brazil’s work with Mozambique and Angola to build stronger 
clinical research capacity. Brazil is to help strengthen Portuguese speaking African countries’ public health research 
activities through educational linkages. Fiocruz is to coordinate a project which sees Brazilian researchers support a 
Masters course in public health research to be run at the Angola National School of Public Health. If successful the 
project will be rolled out to Mozambique and other countries. The project, supported by the Angolan government and 
Capes, Brazil’s federal research funding agency, allows Brazilian researchers to teach on the two year Master’s course 
in Angola and for Angolan students to spend three months of their second year in Brazil doing research and writing 
their dissertations at Fiocruz. The course will begin in October 2006. Distance learning branches will be set up in Cape 
Green, Guinea Bissau and Sao Tome and Principe. The project will also provide the Masters students with free access 
to 10,000 online journals. Future plans for the project include renovating Angola’s technical schools and libraries. The 
project builds on a programme at Fiocruz which during the 1980s and 1990s saw Fiocruz receive 30 students from 
Portuguese-Speaking African Countries and East Timor, supported by the Japanese International Cooperation Agency 
(Jica).   
 
BOX 8: The European and Developing Countries Clinical Trials Partnership 
 
Set up in 2003 this is a partnership between 14 European Union countries, Switzerland, Norway and African 
countries with the aim to develop new drugs and vaccines to fight HIV/AIDS, tuberculosis and malaria through joint 
research programmes that would share information and resources. An example of north-south and south-south 
collaboration and networking to build scientific capacity to conduct clinical trials in developing countries, the 
EDCTP was developed with developing country scientists involved at every step (Binka, 2004). However, despite 
this, and perhaps because of the size of the initiative – the EDCTP has been criticised for not processing trial grants 
quickly enough; some researchers who submitted trial proposals two years ago still have not received a reply 
(www.scidev.net, Sept 2006). A recent report (IAVI, 2006) highlights that of the € 200million committed to the 
EDCTP published data suggests less than 5% of this money (only € 8.3million) has been disbursed. 
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4.3 Making the most of health innovation networks 
 
The value of health innovation networks can be found in their network activities, the emphasis placed on collaboration 
between groups with common purpose. The development of ‘mode 2’, which links academics, applied and product 
development researchers and user groups in health innovation efforts ensures more is achieved together than by going it 
alone. The need to integrate has become common within a number of industries particularly for health innovation in 
pharmaceuticals (Henderson, Orsenigo and Pisano, 1999) and with ‘partnerships’ seen as solutions to development 
problems (Crewe and Harrison, 1998). We have moved into a ‘shared power world’ (Bryson and Crosby, 2002) where 
actors are better served when better connected (Burt, 2002) in an increasingly networked society (Castells, 1996). The 
value of networks in health innovation can be found, as highlighted above, at all levels. Health innovation networks 
such as MMV prove useful at brokering knowledge between entities across national boundaries at the international 
level. At the same time, the power and value of local networks on international activities is evidenced by the work of 
the AAVP. The examples highlight how important such networked relations are at providing a brokering mechanism for 
groups with common interests. 
 
Many of the networks not only emphasise capacity building and strengthening of a wider health innovation system in 
which they are a part but create opportunities for this to occur as a result of the networked arrangements in which 
activities take place. The KEMRI-Wellcome Trust Research Programme and AMANET both build local capacity to 
conduct research and embed their activities within the communities and health sectors in which they work. The work of 
MMV places an immediate emphasis on networking to ensure successful development of anti-malarials. In order for 
this to occur training and other capacity building activities take place. Again, the benefits of linking research to 
innovation efforts are clear. 
 
BOX 9: AMANET & AAVP 
 
The African Malaria Network Trust (AMANET) 
AMANET started life in 1995 as the African Malaria Vaccine Testing Network and is a network of African 
organisations with external assistance aiming to develop African capacity to conduct malaria vaccine clinical trial 
work. The change to AMANET occurred in 2002 with recognition of a need for capacity to be built in other areas of 
malaria research activities with a more integrated approach to malaria research activities. AMANET’s mission is to 
"Promote Capacity Strengthening and Networking of Malaria Research and Development in Africa". AMANET 
builds both human capacity through conducting training workshops and infrastructural capacity through provision of 
equipment and facilities. AMANET also funds clinical and field trials themselves. AMANET has a permanent 
secretariat based in Tanzania coordinating activities through scientific and trial site committees. The governance of 
AMANET occurs through a General Assembly and Board of Trustees format made up of representatives working in 
malaria research focusing on Africa. 
 
African AIDS Vaccine Programme (AAVP) 
A WHO-UNAIDS supported programme, the AAVP was initiated by a group of African scientists in 2000 who 
“adopted "The Nairobi Declaration: An African Appeal for an AIDS Vaccine", pledging to use their personal and 
collective commitment and expertise in the development and implementation of an African Strategy for AIDS 
Vaccines.” (www.who.int). The secretariat is housed within the WHO-UNAIDS HIV Vaccine Initiative in Geneva 
providing technical, financial and secretarial support to the AAVP. Working around thematic working groups, 
overseen by a steering committee made up of 8 African scientists, the AAVP aims to accelerate HIV vaccine work to 
ensure development of effective HIV vaccines for Africa. 
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Health innovation networks are evolving across the continent on an international, sub-regional and regional basis. Using 
case studies we can look at the ways in which national structures and sub-regional and regional institutions can support 
and facilitate each other. Establishing solid relationships between national institutions and sub-regional and regional 
initiatives is vital to sustainability.   
 
 
5.  The International Community 
 
In this section we discuss the following question: 
- What role can the international community play in assisting in the building of health 
innovation systems and networks?  
 
The international community has a vital role in building health innovation systems in Africa. In an increasingly 
globalised world no one part of the world can operate in isolation. In building financial, human and institutional 
resource multiple international connections need constructing and sustaining. International policy needs to take into 
account the importance of building health innovation systems in Africa and international funds need to be targeted to 
the challenges of meeting related immediate and longer term goals. 
 
In funding research and innovation the international community, particularly donors are often committed to supporting 
‘excellence’. However, what constitutes excellence is a thorny and contentious issue. To what extent should funding be 
directed to exciting basic science that will score highly on traditional indicators of excellence, i.e. highly cited peer 
reviewed publications and perhaps patents, and to what extent should efforts be directed at more applied work 
addressing pressing social, health and economic targets? What are the measures that can be used to measure excellence 
for this type of work? Should international donors support regional centres of excellence or is this a model that 
inevitably leads to ‘ivory tower’ establishments that are unable to forge the networks and connections needed to address 
the problems of African countries? These issues are being widely discussed currently.6 The perspective we have 
adopted in this paper is that there is scope for coordinating and integration efforts to build scientific and research 
capacity and building innovation capacity. There is no model that will yield results in all contexts and support of high 
quality dynamic initiatives is crucial. 
 
Another set of issues relate to how global ‘vertical’ or dedicated initiatives, which receive very significant amounts of 
donor funding, such as the GFATM, the Global Alliance for Vaccines and Immunisation (GAVI), and IAVI can be used 
to support the larger and broader health innovation system and health system goals of African countries. Whilst the 
impact of these initiatives has not always been judged to have a positive impact on national health structures and 
operations (Buse and Harmer, 2007) there is good evidence to suggest that in some cases these initiatives have had a 
positive impact on capacity building in some areas.   
 
IAVI presents an important capacity building example of the relationship between research ‘for’ developing countries 
                                                 
6 There is an active and interesting discussion about the relevance of Centres of Excellence in Africa on www.scidev.net currently, 
for example, and the issue is being discussed in a number of policy fora.  
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and research ‘with’ developing country partners, not just research ‘in’ developing countries. The need for a preventative 
vaccine against HIV/AIDS is overwhelmingly evident as is the emphasis on the fastest and most effective way of 
achieving that target. However, a close look at the main PPP working on a preventative vaccine, IAVI, suggests that 
even here the distinction between ‘for’ and ‘with’ need not be so clear cut — IAVI has in fact had very positive impacts 
in terms of capacity building. In this case (see Box 10), political and ethical sensitivities around vaccine development 
and clinical trials are powerful arguments in favour of local engagement and voice at all levels (Chataway and Smith 
2006). 
 
Overall, this product-based approach to capacity building seems to have important lessons for those thinking about S&T 
capacity building policy. Capacity building can result from initiatives that focus on product development rather than on 
broader and more diffuse initiatives aimed at formal training. The tacit knowledge exchange around the vaccine and 
vaccine preparedness that has taken place as part of the IAVI work is particularly important as a lesson of experience 
for other S&T capacity-building initiatives. 
 
The IAVI experience shows that some of the global initiatives do see that building capacity in developing countries is 
important because support and involvement is essential. At a recent meeting at Wilton Park in the UK two other global 
health initiatives, the GFATM and GAVI also called for more ‘systems’ building in developing countries. The 
reasoning here is different. GAVI and the GFATM both consider that their operations have had very significant success. 
However, their future and the sustained success of their operations depend on better health services and systems in 
developing countries. Investment at this level of national and regional systems is now essential. Thus, there does now 
seem to an opportunity to build momentum for investment in systems building in developing countries. There is 
considerable scope for creative policy aimed at fostering capacity in health innovation and health systems. 
 
 
BOX 10: The International AIDS Vaccine Initiative  
 
IAVI was set up in 1996 with the aim of promoting the creation and distribution of an effective preventative AIDS 
vaccine. IAVI acts as a sort of venture capitalist, investing in promising vaccine candidates and offering support 
for the expensive clinical-trial stage of drug development. IAVI also engages in high-profile public relations and 
grassroots advocacy work, particularly vaccine preparedness work, to promote the need for a vaccine and to 
provide insight into technological possibilities. A crucial part of IAVI’s work is developing strong links – 
partnerships – with developing country institutions to run clinical trials and vaccine preparedness work or planning 
for vaccine manufacturing and distribution.  
 
IAVI has achieved significant capacity building through its partnerships. IAVI’s role in capacity building is 
paradoxical but successful. Capacity building is not a core priority but it is strategically important. Capacity 
building has been essential to IAVI for three principal reasons. First, for scientific reasons it is essential that 
clinical trials be conducted among those populations for whom the drug is intended. Second, building support 
for a vaccine requires local political support and this is built through active engagement. Third, the majority of 
IAVI’s funding now comes from bilateral and multilateral funding agencies and these agencies clearly favour 
a capacity-building approach whereever possible. 
 
IAVI partners in Kenya, Uganda, and Rwanda have all received very significant investment in training and 
infrastructure, and have benefited in particular from close and constant communication via telephone, Internet, and 
face-to-face meetings with leading scientists and managers. IAVI’s African partners say it is the constantly focused 
activity around a set of tasks associated with vaccine development that has been particularly valuable. For partner 
organizations in Uganda, Kenya and Rwanda, new prospects have opened up as a result of this engagement and 
hey can now aim realistically to be centres of excellence for the development of vaccine clinical trials.  
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6. Policy recommendations 
 
In this section we discuss the following question: 
- What specific policy and institutional reforms need to be considered by African 
governments? 
 
At present, as we have shown earlier, the institutional set-up and range of policy perspectives in health innovation has a 
number of ‘disconnects’. These disconnects exist everywhere and not only in Africa, but they are bigger in countries 
with weaker resource bases. In section 2 we summarised the issue as a worrying and endemic gap between social 
policies on the one hand and industrial and innovation policies on the other. To put it bluntly, health policy and national 
health ‘systems’ tend, if at all, to treat innovation as irrelevant – for health product procurers, health products can be 
obtained just as easily or with just as much difficulty anywhere in the world. This leads, not only to importation of most 
drugs, but often importation of the most basic hospital and clinic equipment and instrumentation.   
 
We write in section 2 of the lack of understanding between those who research and make policy in the world of health 
care and those whose interest is in health innovation and production of pharmaceuticals. Obviously then, institutions 
reflect this gap, and policies so far have not integrated social policy and the production policy. In fact health policy 
tends to deal with partial analysis of healthcare systems (Mackintosh and Koivusalo, 2005) with little 
acknowledgement of wider areas of activity such as S&T research. At the same time S&T policy has not generally 
focused on health related matters because health has not been strategically important to national growth in many 
countries (Freeman and Miller, 2001).   
 
Increasingly, however, there is recognition that S&T, particularly biotechnology related research and development 
(R&D), is an important part of the health system and that developing countries must develop their own R&D capacity if 
they are to achieve sustainable health systems and the Millennium Development Goals are to be reached (Mugabe, 
2005; Csaszar and Lal, 2004). Mahoney and colleagues have developed the idea of a ‘health innovation system’ around 
the six determinants of health innovation, summarised in section 2 of R&D; manufacturing; internal markets; export 
markets; IP; and regulation. The large health product development projects (like IAVI and MMV) have, in some 
respects, kick-started integration through doing it, focused on the big killers. Other studies, like the Rockefeller Report 
on Intellectual Property suggest, just as do the literatures reviewed in section 1 that working on all fronts at once is key. 
For example, the ability to build capabilities in partnership working and managing large projects or sub-projects 
depends on existing or developing the systems-making connections in R&D, regulation, IP etc are necessary. But what 
matters most is pulling them together. Developing them separately without dialogue or connection, is not only slower, 
but will not work if the idea is to link the satisfaction of health needs with the capacity to deliver them. 
 
In this section we focus on some key policy issues that are relevant for better integration of the social and technical 
aspects of health innovation systems. 
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6.1 Linking health policy and health innovation systems 
 
The cases discussed in section 3 illustrate that despite limitations (knowledge, finance, political and economic upheaval, 
large populations) some developing countries have found actions and strategies to establish a S&T base. They are now 
making efforts to integrate diverse science based disciplines such as biotechnology, bioinformatics and IT into health 
innovation and health care services.  
 
Some more advanced developing countries, such as Brazil, China, India, Cuba and South Africa are increasing funding 
drug development related research and commercialization activities. Biotechnology R&D is generating a large number 
of new technologies. Some of their pharmaceutical companies have entered international markets with both generics 
and self-developed products. These countries and others are improving their drug regulatory agencies and are adopting 
relevant laws and regulations for IP management as well. In short, they are pushing forward on all of Mahoney’s six 
determinants and the additional capability of organizational capacity. However, it is clear that results for even these five 
advantaged countries are not uniformly positive. Some countries (India and South Africa) have improved their health 
innovation capacity but have relatively weak overall standards of health care. Others, like Cuba, have relatively good 
health systems and impressive health care standards.  
 
Clearly, these countries are not representative of developing countries generally, including most African countries. 
They do, however, provide policy perspectives for those with strong ambitions to improve health innovation systems 
rapidly. To turn ambition into new practices involves radical internal transformations at national, regional and continent 
level, and massive support from the international community. 
 
Overall, we would still argue that countries with strong health innovation foundations, if they choose to, are well placed 
to succeed in developing and sustaining good health systems, and vice versa. Countries with better health innovation 
systems can participate in south-south efforts to improve conditions in weaker countries and regions. Recent academic 
analysis is focusing on ways in which innovation and industrial policy and social provision impact on one another and 
can be constructed in ways that are mutually supportive.  
 
One policy action that the African Union and NEPAD might consider is initiating an expert group to develop analysis 
and promote policy initiatives and mechanisms to integrate health related industrial and innovation policy on the one 
hand and healthcare policy on the other hand. The expert group would formulate policy plans and stimulate activities. 
The group would include policy makers, private sector actors and academics.  
 
Another suggestion is linked to a capacity building action already outlined in the African Union and NEPAD Science 
and Technology Consolidated Plan of Action. As part of its science and technology capacity building the Consolidated 
Plan suggests Short-term Executive Workshops for Senior Government Officials. We suggest that some of these 
workshops be designed around building health innovation systems and specifically around the need to bridge the gap 
between different areas of policy.   
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6.2 The importance of building on and integrating global programmes 
 
Huge investments are currently being made in global health programmes and these programmes offer an opportunity to 
foster innovation and integrate better the health services and health innovation systems, given that they focus not only 
on producing new technologies for treatment but also on delivery to huge populations. The challenge, which would be 
revolutionary if successful, is to build integrated systems that build on existing services and capabilities rather than act 
as a parallel system, further fragmenting existing national and regional systems. The great strength of the global health 
partnerships and other international initiatives like Wellcome Trust efforts for example is that they aim to develop and 
use innovative capacities from around the world and link them to available capacity in countries with the biggest 
disease killers. The policy challenge is how to use the new resources to change health systems sustainably. The global 
health programme could, if they built on each of the six determinants of innovation, be part of the glue that binds 
governments and voluntary health sectors with local research institutes and universities, looking for the best local 
institutes to work with. Some instances where this does seem to be happening was presented in section 4. A further case 
study is presented in Section 5.  
 
From Africa’s side, local institutions could be encouraged to explicitly work to build better conditions for learning from 
these huge global initiatives and global partnerships and construct a myriad of global connections – avoiding passive 
sub-contracting and actively learning in order to imitate and innovate.   
 
One policy recommendation is for NEPAD and the African Union pursue further discussion with international Global 
Health Programmes such as GAVI and the GFATM about how these initiatives could best support health innovation 
capacity building in African countries.  Discussions along the same lines might also be pursued with some of the large 
public private partnerships such as IAVI and MMV. 
 
6.3 The importance of balancing innovation and its regulation 
 
Another policy challenge is to ensure that the pressures for innovation are in balance with those for regulation and 
governance. The High-Level Panel on Modern Biotechnology of the African Union and NEPAD in their report 
Biotechnology in Africa’s Development which was focused on biotechnology but may well have more general import, 
pinpointed one danger: “The evolution of [Africa’s biotechnology] regulatory systems has been largely influenced by 
international debates that are often not directly associated with the technological needs of the continent. The continent, 
through its regional economic communities, needs to adopt an evolutionary approach where regulatory systems develop 
hand in hand with technological opportunities and applications”. It goes on to advocate risk taking and care at the same 
time, not to allow the risk to stop innovation happening.  
 
The balancing act will require great policy finesse, and also significant resources. Regional initiatives will be needed to 
support local efforts. Efforts should build on WHO initiatives. Concerted efforts should be made to develop systems 
that are enabling rather than constraining and should be consistent with the detailed policy recommendations developed 
in the report on Biotechnology in Africa’s Development.  
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6.4 Capacity building for more integrated innovation systems 
 
This paper has outlined several ways in which health networks can contribute to building innovation capacity in Africa. 
We have argued that national institutions and organizations can use networks and partnerships to develop health 
innovation and provision. This analysis of capacity building possibilities builds on work that NEPAD has already 
carried out on thinking related to centres of excellence in Africa and we would endorse the policy perspectives and 
actions outlined in the document ‘Centers of Excellence in Science and Technology for Africa’s Sustainable 
Development’.7  
 
Throughout this document we have also emphasized the importance of building on dynamic initiatives and trying to 
maximize national and regional capacity from initiatives which show promise. This thinking around building regional 
networks of excellence and grounding them where appropriate in national and regional institutions needs further 
development. Universities can clearly play a key role in interacting with and supporting networks and a clear policy 
recommendation is that Africa’s academies of science consider ways to promote and extend health innovation networks 
in conjunction with African universities. By adopting more ‘mode 2’ approaches and by prioritizing links with other 
researchers, with users groups and with policymakers, African universities could make a fundamental contribution to 
the development of more sustainable health innovation systems. 
 
Universities can also clearly play a key role in providing training in innovation policy and practice that could improve 
health innovation over the medium and longer term. The Consolidated Plan outlines plans for postgraduate training in 
innovation and one policy recommendation would be to offer a modular strand of training on health innovation systems 
and integration with health systems. 
 
6.5 Integrated policy making 
 
This paper has argued for the need to identify and back ‘micro-systems of innovation’ whilst concurrently reforming 
national institutions and policy to provide facilitative innovation environments. This approach requires rethinking the 
way in which much policy is made. Policy formulation itself needs to become a more dynamic and interactive process. 
One policy recommendation, then, is for the African Union and NEPAD to support exercises such as Foresight which 
might help identify promising initiatives and technologies. Foresight exercises tend to work best when based on the 
involvement of substantial numbers of researchers, scientists and policy makers and it may well be that regional 
Foresight initiatives might be appropriate. 
 
                                                 
7 Prepared by John Mugabe for AMCOST 
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